WO2005094835A1 - M3 muscarinic acetylcholine receptor antagonists - Google Patents
M3 muscarinic acetylcholine receptor antagonists Download PDFInfo
- Publication number
- WO2005094835A1 WO2005094835A1 PCT/US2004/008032 US2004008032W WO2005094835A1 WO 2005094835 A1 WO2005094835 A1 WO 2005094835A1 US 2004008032 W US2004008032 W US 2004008032W WO 2005094835 A1 WO2005094835 A1 WO 2005094835A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetrahydro
- benzazepine
- ethyl
- cyclohexyl
- amino
- Prior art date
Links
- 0 C*1C=CC(CC*(CCC(CC2)CCC2*(*)C(*)=O)CC2)=C2C=C1 Chemical compound C*1C=CC(CC*(CCC(CC2)CCC2*(*)C(*)=O)CC2)=C2C=C1 0.000 description 3
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- M MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS FIELD OF THE INVENTION This invention relates to novel thiazole aniline compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating M3 muscarinic acetylcholine receptor mediated diseases.
- BACKGROUND OF THE INVENTION Acetylcholine released from cholinergic neurons in the peripheral and central nervous systems affects many different biological processes through interaction with two major classes of acetylcholine receptors - the nicotinic and the muscarinic acetylcholine receptors.
- Muscarinic acetylcholine receptors belong to the superfamily of G-protein coupled receptors that have seven transmembrane domains. There are five subtypes of mAChRs, termed M1-M5, and each is the product of a distinct gene. Each of these five subtypes displays unique pharmacological properties. Muscarinic acetylcholine receptors are widely distributed in vertebrate organs, and these receptors can mediate both inhibitory and excitatory actions. For example, in smooth muscle found in the airways, bladder and gastrointestinal tract, M3 mAChRs mediate contractile responses,
- Muscarinic acetylcholine receptor dysfunction has been noted in a variety of different pathophysiological states. For instance, in asthma and chronic obstructive pulmonary disease (COPD), inflammatory conditions lead to loss of inhibitory M2 muscarinic acetylcholine autoreceptor function on parasympathetic nerves supplying the pulmonary smooth muscle, causing increased acetylcholine release following vagal nerve stimulation. This mAChR dysfunction results in airway hyperreactivity mediated by increased stimulation of M3 mAChRs. Similarly, inflammation of the gastrointestinal tract in inflammatory bowel disease (IBD) results in M3 mAChR-mediated hypermotility (Oprins, J. C. J., HP. Meijer, and J. A.
- IBD inflammatory bowel disease
- This invention provides for a method of treating a muscarinic acetylcholine receptor (mAChR) mediated disease, wherein acetylcholine binds to an M3 mAChR and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.
- This invention also relates to a method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof which comprises administering to aforementioned mammal an effective amount of a compound of Formula (I).
- the present invention also provides for the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I), and a pharmaceutical carrier or diluent.
- R1 is selected from:the group consisting of a hydrogen or halogen atom; a hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, trifluoromethanesulfonyloxy, pentafluoroethyl, C-
- Ar is selected from a group consisting of an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; or an optionally substituted bicyclic ring system;
- Ar 1 and Ar 2 are, independently, selected from a group consisting of an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring;
- Y is selected from a group consisting of a bond, -NHCO-, -CONH-, -CH -, or
- any substituent present in Ar ortho to the carboxamide moiety is necessarily a hydrogen or a methoxy group; r and s independently represent an integer from zero to 3 such that the sum of r and s is equal to an integer from 1 to 4; and V represents a bond, O or S; and salts thereof.
- A represents a group of formula (a)
- any substituent present in Ar ortho to the carboxamide moiety is necessarily a hydrogen or a methoxy group
- r and s independently represent an integer from zero to 3 such that the sum of r and s is equal to an integer from 1 to 4
- V represents a bond, O or S; and salts thereof.
- an alkyl group or moiety may be straight or branched.
- Alkyl groups which may be employed include methyl, ethyl, n- propyl, n-butyl, n-pentyl, n-hexyl and any branched isomers thereof such as isopropyl, t-butyl, sec-butyl, and the like.
- R 1 represents an arylC-
- the aryl moiety may be selected from an optionally substituted phenyl ring or an optionally substituted 5 or 6-membered heterocyclic ring.
- an aryl moiety may be optionally substituted by one or more substituents selected from hydrogen, halogen, amino, cyano, C ⁇ _4alkyl,
- a halogen atom present in the compounds of formula (I) may be fluorine, chlorine, bromine or iodine.
- the substituents R 1 may be the same or different.
- An optionally substituted 5- or 6-membered heterocyclic aromatic ring, as defined for any of the groups Ar, Ar 1 , Ar 2 or Ar 3 may contain from 1 to 4 heteroatoms selected from O, N or S. When the ring contains 2-4 heteroatoms, one is preferably selected from O, N and S and the remaining heteroatoms are preferably N.
- Examples of 5 and 6-membered heterocyclic groups include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, pyrimidinyl, pyrazolyl, isothiazolyl, and isoxazolyl.
- bicyclic, for example bicyclic aromatic or heteroaromatic, ring systems for Ar include naphthyl, indazolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzisothiazolyl, quinolinyl, quinoxolinyl, quinazolinyl, cinnolinyl, isoquinolinyl, pyrazolo[1 ,5- a]pyrimidyl, pyrrolo[3,2-b]pyridyl, pyrrolo[3,2-c]pyridyl, thieno[3,2-b]thiophenyl, 1 ,2- dihydro-2-oxo-quinolinyl, 3,4-dihydro-3-oxo-2H-benzoxazinyl, 1 ,2-dihydro-2-oxo-3/---
- the rings Ar, Ar 1 , or Ar 2 may each independently be optionally substituted by one or more substituents selected from: a hydrogen or halogen atom, or a hydroxy, oxo, cyano, nitro, trifluoromethyl, C ⁇ alkyl, C- ⁇ alkoxy, C-
- Ar and Ar 2 may be optionally substituted by one or more 5- or 6-membered heterocyclic rings, as defined above, optionally substituted by a C- ⁇ 2 alkyl or R 7 R 8 N- group; wherein R 7 and R 8 are as defined above.
- Ar and Ar 2 substituents positioned ortho to one another may be linked to form a 5- or 6- membered ring.
- salts of formula (I) should be physiologically acceptable.
- suitable physiologically acceptable salts will be apparent to those skilled in the art and include for example acid addition salts formed with inorganic acids eg. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids eg. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid.
- Other non-physiologically acceptable salts eg. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention.
- Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid.
- the present invention includes within its scope all possible stoichiometric and non-stoichiometric forms.
- the compounds of formula (I) can exist in the form of cis- and trans- isomers with respect to the configuration at the cyclohexyl ring.
- A represents a group (c) the compounds may also exist as geometric isomers around the double bond.
- the present invention includes within its scope all such isomers, including mixtures.
- the compounds of the invention are in the trans configuration with respect to the cyclohexyl ring.
- R 1 represents a substituent selected from: a halogen atom, methyl, cyano, acetyl, trifluoromethyl, pentafluoroethyl, methylsulphonyl, methylsulphonyloxy or trifluoromethoxy group.
- R 1 represents a group Ar 3 Z, where Z is a bond and
- Ar 3 is a 5- or 6-membered ring heterocycle, optionally substituted by a methyl group, containing at least one N and one O atom. Preferably q is 1.
- R 2 is preferably a hydrogen atom.
- preferred examples of Ar include optionally substituted phenyl, indolyl, pyrazolo[1 ,5-a]pyrimidyl, cinnolinyl, quinolinyl, benzo[b]furanyl or pyrrolopyridyl.
- Ar 1 When the group A is a group of formula (b), preferred examples of Ar 1 include optionally substituted phenyl, Y is preferably a bond, and preferred examples of Ar 2 include optionally substituted phenyl, pyridyl, pyrimidinyl, isoxazolyl, oxazolyl or oxadiazolyl.
- Ar When the group A is a group of formula (c), preferred examples of Ar include optionally substituted phenyl.
- the rings Ar, Ar 1 , or Ar 2 are each independently optionally substituted by one or more substituents selected from: a hydrogen or halogen atom, cyano, methoxy, trifluoromethyl, methylenedioxy, acetyl, acetylamino, methylsulfonyl, methylsulfonyloxy, methylaminosulfonyl, methylsulfonylamino, or methylaminocarbonyl group.
- substituents selected from: a hydrogen or halogen atom, cyano, methoxy, trifluoromethyl, methylenedioxy, acetyl, acetylamino, methylsulfonyl, methylsulfonyloxy, methylaminosulfonyl, methylsulfonylamino, or methylaminocarbonyl group.
- substituents selected from: a hydrogen or halogen atom, cyano, methoxy, triflu
- Preferred Compounds include: tra ⁇ s-7-Cyano-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl)carboxamido)cyclohexyl)ethyl)-
- Most preferred compounds include: tra/7s-(£)-7-Cyano-3-(2-(1-(4-(5-quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 --benzazepine; trans-7-Cyano-3-(2-(1-(4-(5-(8-fluoro)quinolinyl)carboxamido)cyclohexyl)ethyl)-
- the present invention also provides a process for preparing compounds of formula (I) which process comprises: (a) reacting a compound of formula (II):
- A is as hereinbefore defined and X is a halogen atom or the residue of an activated ester; (b) to prepare a compound of formula (I) by reacting a compound of formula (II) with a compound A-Br, or A-l, or A-OSO 2 CF3 in the presence of carbon monoxide and a catalyst such as frans-b/s-triphenylphosphinepalladium(ll)bromide; (c) to prepare a compound of formula (I) wherein R 1 is Ar 3 -Z and Z is a bond, reacting a compound of formula (IV):
- R 2 and A are as hereinbefore defined and one R 1 a represents a group W wherein W is a halogen atom or a trifluoromethylsulfonyloxy group, or W is a group M selected from a boron derivative e.g. a boronic acid function B(OH) 2 or a metal function such as trialkylstannyl e.g.
- R 2 and A are as hereinbefore defined and one R 1 D represents a group ZH and when q is 2 the other R 1 D represents R 1 ; with a reagent serving to introduce the group Ar 3 ; (e) to prepare a compound of formula (I) where Y is a bond, reaction of a compound of formula (VI):
- W is a halogen atom or a trifluoromethylsulfonyloxy group when W is a group M, or W 1 is a group M when W is a halogen atom or a trifluoromethylsulfonyloxy group.
- R 1 from hydroxy to sulfonyloxy, eg alkylsulfonyloxy or trifluoromethanesulfonyloxy; (iv) conversion of a compound wherein Y represents S to a compound wherein Y is S0 2 or (v) conversion of Y from CO to CH ; (g) separation of cis- and trans- isomers of compounds of formula (I) by conventional methods, e.g. chromatography or crystallisation; and optionally thereafter forming a salt of formula (I).
- Process (a) may be effected using conventional methods for the formation of an amide bond. When X is the residue of an activated ester this may be formed with e.g.
- a carbodiimide such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide.
- the reaction may be carried out in a solvent such as dichloromethane. Reaction of a compound of formula (IV) with Ar 3 W 1 , according to process
- a compound of formula (VI) with Ar 2 -W 1 according to process (e) may be effected in the presence of a transition metal eg palladium catalyst such as bis- triphenylphosphinepalladium dichloride or tetra/ /s-triphenylphosphinepalladium (0).
- a transition metal eg palladium catalyst
- M represents a boronic acid function such as B(OH) 2
- the reaction may be carried out under basic conditions, for example using aqueous sodium carbonate in a suitable solvent such as dioxane.
- M is trialkylstannyl
- the reaction may be carried out in an inert solvent, such as xylene or dioxane optionally in the presence of LiCI.
- the reaction may be effected in an aprotic solvent such as tetrahydrofuran.
- the substituent W is preferably a halogen atom such as bromine, or a sulfonyloxy group such as trifluoromethylsulfonyloxy; and W ⁇ is preferably a group M, such as trialkylstannyl or B(OH) 2 .
- the reagent serving to introduce the group Ar 3 is preferably a compound of formula Ar 3 -Hal, wherein Hal is a halogen atom.
- the reaction may be effected in the presence of a base, such as potassium carbonate, in a solvent such as dimethylformamide.
- Interconversion reactions according to process (f) may be effected using methods well known in the art.
- Compounds of formula (II) may be prepared by conversion of a compound of formula (VII), wherein R ⁇ and q are as hereinbefore defined,
- R 2 NH 2 or ammonium acetate in the presence of a reducing agent.
- Suitable reducing agents which may be employed include sodium borohydride, cyanoborohydride or triacetoxyborohydride under acidic conditions, or catalytic hydrogenation.
- the reaction may conveniently be effected in a solvent such as methanol, ethanol or dichloroethane.
- a compound of formula (VII) may itself be prepared by reacting a compound of formula (VIII):
- the individual cis- and trans- isomers of a compound of formula (II) may be prepared starting from c/?s- or trans- 4-amino-cyclohexaneacetic acid (T.P. Johnson, et al., J. Med. Chem., 1997, (20), 279-290) followed by functional group interchange and/or protection using methods well known in the art, to give the individual cis- or trans- isomers of a compound of formula (X): Formula (X)
- R 2 is as hereinbefore defined, and P is a protecting group, for example trifluoroacetyl or tert-butoxycarbonyl.
- P is a protecting group, for example trifluoroacetyl or tert-butoxycarbonyl.
- a compound of formula (X) with a compound of formula (VIII) in the presence of a reducing agent as described above followed by deprotection using standard methodology gives the individual isomers of a compound of formula (II) wherein R 2 is as hereinbefore defined.
- Compounds of formula (III) are known or may be prepared using standard procedures.
- Compounds of formula (IV), (V) or (VI) may be prepared by processes analogous to (a), (b), (c) and (d) described above.
- Ar 3 Hal are commercially available or may be prepared by standard methods.
- Conversion of a compound of formula (VIII) where R 1 is a cyano or acetyl group to a compound of formula (VIII) where R 1 is a group Ar 3 Z, where Ar is an oxadiazole or an isoxazole ring and Z is a bond may be carried out by (i) conversion to a compound of formula (XI), where R ⁇ and q are as hereinbefore defined, using standard methods; (ii) conversion of R 1 from cyano to oxadiazolyl using known methods, or conversion of acetyl to isoxazolyl using known methods; (iii) deprotection of a compound of formula (XI) to a compound of formula (VIII) using standard methods.
- reaction mixture was cooled to room temperature and partitioned between water (50 ml) and ethyl acetate (100 ml). The aqueous layer was then separated and further extracted with ethyl acetate (2 x 80 ml). The combined organics were then dried (Na 2 SO4) and the solvent removed in vacuo to give the title compound (1.77 g, 73 %) as a pale yellow solid.
- the oily suspension was then extracted with ethyl acetate (3 x 60 ml) and the combined organic layers dried (Na 2 S ⁇ 4).
- the solvent was evaporated in vacuo to give the title compound (1.01 g, 100 %) as an off-white solid.
- the aqueous layer was then basified to pH 14 with 40% sodium hydroxide.
- the suspension was then extracted with ethyl acetate (3 x 80 ml) and the combined organic layers dried (Na 2 S ⁇ 4).
- the solvents were evaporated in vacuo to give the title compound (1.78 g, 93 %) as an oil which crystallised on standing.
- the substituted benzazepines required as intermediates for the compounds of Table 5 were prepared from the compounds of Descriptions 8, 9, or 13, using standard methods for functional group transformation and heterocyclic ring synthesis or by palladium-catalysed cross-coupling reactions.
- the reaction mixture was washed with saturated aqueous sodium bicarbonate (4 ml).
- the organic layer was pipetted onto a 10 g pre-packed silica column and eluted with 30 - 100% ethyl acetate in hexane.
- the fractions containing the title compound were combined and evaporated in vacuo to give the title compound (119 mg, 71%) as a colourless solid.
- Example 17 frans-7-Cyano-3-(2-(1-(4-(6-(3,4-dihydro-3-oxo)-2H- benzoxazinyl)carboxamido)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H- benzazepine
- a mixture of tra ⁇ s-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-cyano-2,3,4,5-tetrahydro- 1 H-3-benzazepine (0.10 g, 0.34 mmol), 2,3-dihydro-3-oxo-4 --benzoxazine-6- carboxylic acid (0.072 g, 0.42 mmol), 1 -ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (0.071 g, 0.42 mmol), 1- hydroxybenzotriazole (catalytic amount) and dich
- reaction mixture was washed with saturated aqueous sodium bicarbonate (4 ml) and the precipitate collected by filtration and then re-suspended in water and filtered before drying in vacuo to give the title compound as an off white solid (200 mg, 79%).
- the organic phase was purified by silica gel chromatography eluting with 30-100% ethyl acetate in hexane, then 0 - 10 % methanol in ethyl acetate gradient elution to give the title compound (0.095 g, 70 %) as a colourless solid.
- inhibitory effects of compounds at the M3 mAChR of the present invention are determined by the following in vitro and in vivo functional assays:
- CHO cells stably expressing M3 mAChRs were plated in 96 well black wall/clear bottom plates. After 18 to 24 hours, media was aspirated and replaced with 100 ⁇ l of load media (EMEM with Earl's salts, 0.1% RIA-grade BSA (Sigma, St. Louis MO), and 4 ⁇ M Fluo-3-acetoxymethyl ester fluorescent indicator dye (Fluo-3 AM, Molecular Probes, Eugene, OR) and incubated 1 hr at 37° C.
- load media EMEM with Earl's salts, 0.1% RIA-grade BSA (Sigma, St. Louis MO)
- Fluo-3-acetoxymethyl ester fluorescent indicator dye Fluo-3 AM, Molecular Probes, Eugene, OR
- the dye-containing media was then aspirated, replaced with fresh media (without Fluo-3 AM), and cells were incubated for 10 minutes at 37° C.
- Cells were then washed 3 times and incubated for 10 minutes at 37° C in 100 ⁇ l of assay buffer (0.1% gelatin (Sigma), 120 mM NaCI, 4.6 mM KCI, 1 mM KH 2 PO 4 , 25 mM NaH CO3, 1.0 mM CaCI 2 , 1.1 mM MgCI 2 , 11 mM glucose, 20mM HEPES (pH 7.4)).
- 50 ⁇ l of compound (1x10 "1 1 - 1x10 "5 M final in the assay) was added and the plates were incubated for 10 min. at 37° C.
- mice were pretreated with 50 ⁇ l of compound (0.003-10 ⁇ g/mouse) in 50 ⁇ l of vehicle (10% DMSO) intranasally, i.v., i.p. or p.o, and were then placed in the plethysmography chamber. Once in the chamber, the mice were allowed to equilibrate for 10 min before taking a baseline Penh measurement for 5 minutes. Mice were then challenged with an aerosol of methacholine (10 mg/ml) for 2 minutes. Penh was recorded continuously for 7 min starting at the inception of the methacholine aerosol, and continuing for 5 minutes afterward.
- the present compounds are useful for treating a variety of indications, including but not limited to respiratory-tract disorders such as chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis; gastrointestinal-tract disorders such as irritable bowel syndrome, spasmodic colitis, gastroduodenal ulcers, gastrointestinal convulsions or hyperanakinesia, diverticulitis, pain accompanying spasms of gastrointestinal smooth musculature; urinary-tract disorders accompanying micturition disorders including neurogenic pollakisuria, neurogenic bladder, nocturnal enuresis, psychosomatic bladder, incontinence associated with bladder spasms or chronic cystitis, urinary urgency or pollakiuria, and motion sickness.
- respiratory-tract disorders such as chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphy
- Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator.
- Formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier substance) such as lactose or starch. Use of lactose is preferred.
- a suitable powder base such as lactose or starch.
- lactose is preferred.
- Each capsule or cartridge may generally contain between 20 ⁇ g-10mg of the compound of formula (I) optionally in combination with another therapeutically active ingredient.
- the compound of the invention may be presented without excipients.
- the medicament dispenser is of a type selected from the group consisting of a reservoir dry powder inhaler (RDPI), a multi-dose dry powder inhaler (MDPI), and a metered dose inhaler (MDI).
- reservoir dry powder inhaler it is meant an inhaler having a reservoir form pack suitable for comprising multiple (un-metered doses) of medicament in dry powder form and including means for metering medicament dose from the reservoir to a delivery position.
- the metering means may for example comprise a metering cup, which is movable from a first position where the cup may be filled with medicament from the reservoir to a second position where the metered medicament dose is made available to the patient for inhalation.
- multi-dose dry powder inhaler is meant an inhaler suitable for dispensing medicament in dry powder form, wherein the medicament is comprised within a multi-dose pack containing (or otherwise carrying) multiple, define doses (or parts thereof) of medicament.
- the carrier has a blister pack form, but it could also, for example, comprise a capsule-based pack form or a carrier onto which medicament has been applied by any suitable process including printing, painting and vacuum occlusion.
- the formulation can be pre-metered (eg as in Diskus, see GB 2242134 or Diskhaler, see GB 2178965, 2129691 and 2169265) or metered in use (eg as in Turbuhaler, see EP 69715).
- the Diskus inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing a compound of formula (I) preferably combined with lactose.
- the strip is sufficiently flexible to be wound into a roll.
- the lid sheet and base sheet will preferably have leading end portions which are not sealed to one another and at least one of the said leading end portions is constructed to be attached to a winding means. Also, preferably the hermetic seal between the base and lid sheets extends over their whole width.
- the lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet.
- the multi-dose pack is a blister pack comprising multiple blisters for containment of medicament in dry powder form.
- the blisters are typically arranged in regular fashion for ease of release of medicament therefrom.
- the multi-dose blister pack comprises plural blisters arranged in generally circular fashion on a disc-form blister pack.
- the multi- dose blister pack is elongate in form, for example comprising a strip or a tape.
- the multi-dose blister pack is defined between two members peelably secured to one another. US Patents Nos. 5,860,419, 5,873,360 and 5,590,645 describe medicament packs of this general type.
- the device is usually provided with an opening station comprising peeling means for peeling the members apart to access each medicament dose.
- the device is adapted for use where the peelable members are elongate sheets which define a plurality of medicament containers spaced along the length thereof, the device being provided with indexing means for indexing each container in turn. More preferably, the device is adapted for use where one of the sheets is a base sheet having a plurality of pockets therein, and the other of the sheets is a lid sheet, each pocket and the adjacent part of the lid sheet defining a respective one of the containers, the device comprising driving means for pulling the lid sheet and base sheet apart at the opening station.
- metered dose inhaler it is meant a medicament dispenser suitable for dispensing medicament in aerosol form, wherein the medicament is comprised in an aerosol container suitable for containing a propellant-based aerosol medicament formulation.
- the aerosol container is typically provided with a metering valve, for example a slide valve, for release of the aerosol form medicament formulation to the patient.
- the aerosol container is generally designed to deliver a predetermined dose of medicament upon each actuation by means of the valve, which can be opened either by depressing the valve while the container is held stationary or by depressing the container while the valve is held stationary.
- the valve typically comprises a valve body having an inlet port through which a medicament aerosol formulation may enter said valve body, an outlet port through which the aerosol may exit the valve body and an open/close mechanism by means of which flow through said outlet port is controllable.
- the valve may be a slide valve wherein the open/close mechanism comprises a sealing ring and receivable by the sealing ring a valve stem having a dispensing passage, the valve stem being slidably movable within the ring from a valve-closed to a valve-open position in which the interior of the valve body is in communication with the exterior of the valve body via the dispensing passage.
- the valve is a metering valve.
- the metering volumes are typically from 10 to 100 ⁇ l, such as 25 ⁇ l, 50 ⁇ l or 63 ⁇ l.
- the valve body defines a metering chamber for metering an amount of medicament formulation and an open/close mechanism by means of which the flow through the inlet port to the metering chamber is controllable.
- the valve body has a sampling chamber in communication with the metering chamber via a second inlet port, said inlet port being controllable by means of an open/close mechanism thereby regulating the flow of medicament formulation into the metering chamber.
- the valve may also comprise a 'free flow aerosol valve' having a chamber and a valve stem extending into the chamber and movable relative to the chamber between dispensing and non-dispensing positions.
- the valve stem has a configuration and the chamber has an internal configuration such that a metered volume is defined therebetween and such that during movement between is non- dispensing and dispensing positions the valve stem sequentially: (i) allows free flow of aerosol formulation into the chamber, (ii) defines a closed metered volume for pressurized aerosol formulation between the external surface of the valve stem and internal surface of the chamber, and (iii) moves with the closed metered volume within the chamber without decreasing the volume of the closed metered volume until the metered volume communicates with an outlet passage thereby allowing dispensing of the metered volume of pressurized aerosol formulation.
- a valve of this type is described in U.S. Patent No. 5,772,085. Additionally, intra-nasal delivery of the present compounds is effective.
- the medicament To formulate an effective pharmaceutical nasal composition, the medicament must be delivered readily to all portions of the nasal cavities (the target tissues) where it performs its pharmacological function. Additionally, the medicament should remain in contact with the target tissues for relatively long periods of time. The longer the medicament remains in contact with the target tissues, the medicament must be capable of resisting those forces in the nasal passages that function to remove particles from the nose. Such forces, referred to as 'mucociliary clearance', are recognised as being extremely effective in removing particles from the nose in a rapid manner, for example, within 10-30 minutes from the time the particles enter the nose.
- a nasal composition is that it must not contain ingredients which cause the user discomfort, that it has satisfactory stability and shelf-life properties, and that it does not include constituents that are considered to be detrimental to the environment, for example ozone depletors.
- a suitable dosing regime for the formulation of the present invention when administered to the nose would be for the patient to inhale deeply subsequent to the nasal cavity being cleared. During inhalation the formulation would be applied to one nostril while the other is manually compressed. This procedure would then be repeated for the other nostril.
- a preferable means for applying the formulation of the present invention to the nasal passages is by use of a pre-compression pump. Most preferably, the pre- compression pump will be a VP7 model manufactured by Valois SA.
- the VP7 model may be used with a bottle capable of holding 10-50ml of a formulation. Each spray will typically deliver 50-1 OO ⁇ l of such a formulation, therefore, the VP7 model is capable of providing at least 100 metered doses.
- Nasal Formulations Example 1 Nasal formulation containing active A formulation for intranasal delivery was prepared with ingredients as follows: to 100% Active 0.1% w/w
- EDTA 0.015% w/w water to 100% in a total amount suitable for 120 actuations and the formulation was filled into a bottle fitted with a metering valve adapted to dispense 50 or 100 ⁇ l per actuation.
- the device was fitted into a nasal actuator (Valois).
- Example 2 Nasal formulation containing active
- a formulation for intranasal delivery was prepared with ingredients as follows: Active 0.005% w/w
- EDTA 0.015% w/w water to 100% in a total amount suitable for 120 actuations and the formulation was filled into a bottle (plastic or glass) fitted with a metering valve adapted to dispense 50 or 100 ⁇ l per actuation
- the device was fitted into a nasal actuator (Valois, e.g. VP3, VP7 or VP7D)
- Example 3 Nasal formulation containing active
- a formulation for intranasal delivery was prepared with ingredients as follows: active 0.05% w/w Triton X- 100 5% w/w
- EDTA 0.015% w/w water to 100% in a total amount suitable for 120 actuations and the formulation was filled into a bottle fitted with a metering valve adapted to dispense 50 or 100 ⁇ l per actuation.
- Example 4 Nasal formulation containing active
- a formulation for intranasal delivery was prepared with ingredients as follows: active 0.05% w/w
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
Description
M MUSCARINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS FIELD OF THE INVENTION This invention relates to novel thiazole aniline compounds, pharmaceutical compositions, processes for their preparation, and use thereof in treating M3 muscarinic acetylcholine receptor mediated diseases. BACKGROUND OF THE INVENTION Acetylcholine released from cholinergic neurons in the peripheral and central nervous systems affects many different biological processes through interaction with two major classes of acetylcholine receptors - the nicotinic and the muscarinic acetylcholine receptors. Muscarinic acetylcholine receptors (mAChRs) belong to the superfamily of G-protein coupled receptors that have seven transmembrane domains. There are five subtypes of mAChRs, termed M1-M5, and each is the product of a distinct gene. Each of these five subtypes displays unique pharmacological properties. Muscarinic acetylcholine receptors are widely distributed in vertebrate organs, and these receptors can mediate both inhibitory and excitatory actions. For example, in smooth muscle found in the airways, bladder and gastrointestinal tract, M3 mAChRs mediate contractile responses,
(1989. The Muscarinic Receptors. The Humana Press, Inc., Clifton, NJ). Muscarinic acetylcholine receptor dysfunction has been noted in a variety of different pathophysiological states. For instance, in asthma and chronic obstructive pulmonary disease (COPD), inflammatory conditions lead to loss of inhibitory M2 muscarinic acetylcholine autoreceptor function on parasympathetic nerves supplying the pulmonary smooth muscle, causing increased acetylcholine release following vagal nerve stimulation. This mAChR dysfunction results in airway hyperreactivity mediated by increased stimulation of M3 mAChRs. Similarly, inflammation of the gastrointestinal tract in inflammatory bowel disease (IBD) results in M3 mAChR-mediated hypermotility (Oprins, J. C. J., HP. Meijer, and J. A.
Groot. 2000. Tumor Necrosis Factor-{alpha} Potentiates Ion Secretion Induced by Muscarinic Receptor Activation in the Human Intestinal Epithelial Cell Line HT29cl.19A. Ann NY Acad Sci 915:102-106). Incontinence due to bladder hypercontractility has also been demonstrated to be mediated through increased stimulation of M3 mAChRs. Thus the identification of subtytpe-selective mAChR antagonists may be useful as therapeutics in these mAChR-mediated diseases.
Despite the large body of evidence supporting the use of anti-muscarinic receptor therapy for treatment of a variety of disease states, relatively few anti- muscarinic compounds are in use in the clinic. Thus, there remains a need for novel compounds that are capable of causing blockade at M3 mAChRs. Conditions associated with an increase in stimulation of M3 mAChRs, such as asthma, COPD,
IBD and urinary incontinence would benefit by compounds that are inhibitors of mAChR binding.
SUMMARY OF THE INVENTION This invention provides for a method of treating a muscarinic acetylcholine receptor (mAChR) mediated disease, wherein acetylcholine binds to an M3 mAChR and which method comprises administering an effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof. This invention also relates to a method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof which comprises administering to aforementioned mammal an effective amount of a compound of Formula (I). The present invention also provides for the novel compounds of Formula (I), and pharmaceutical compositions comprising a compound of Formula (I), and a pharmaceutical carrier or diluent.
Compounds of Formula (I) useful in the present invention are represented by the structure:
C-| _4alkoxyCι _4alkyl, C3_6cycloalkylC-| _4alkoxy, C-| ^alkoxycarbonyl,
C-|_4alkylsulfonyl, C-| ^alkylsulfonyloxy, Cι_4alkylsulfonylC-|-4alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC-i^alkyl, C-^alkylsulfonamido, C-i^alkylamido, C-| _4alkylsulfonamidoC-| ^alkyl, C-j _4alkylamidoC-| ^alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC-|.4alkyl or a arylcarboxamidoC-] ^alkyl group; a group R3OCO(CH )p, R3CON(R4)(CH2)p, R3R4NCO(CH2)p and R3R4NSO2(CH2)p; where each of R3 and R4 is, independently, selected from a group consisting of a hydrogen atom and a C-^alkyl group or R3R4 forms part of a C3_6azacyloalkane or C3_6(2-oxo)azacycloalkane ring and p represents zero or an integer from 1 to 4; or a group Ar3-Z, wherein Ar3 represents an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring and Z represents a bond, O, S , or CH2; R2 is selected from the group consisting of a hydrogen atom or a C-j^alkyl group; q is 1 or 2; A is selected from the group consisting of a group of the formula (a), (b) (c) and (d):
-Ar — Ar3— Y-Ar2 ^^Ar (CH2) — V— (CH2)sAr (a) (b) (c) (d)
wherein
Ar is selected from a group consisting of an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; or an optionally substituted bicyclic ring system; Ar1 and Ar2 are, independently, selected from a group consisting of an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; and Y is selected from a group consisting of a bond, -NHCO-, -CONH-, -CH -, or
-(CH2)mY1 (CH2)n-, wherein Y1 represents O, S, SO2, or CO and m and n each represent zero or 1 such that the sum of m+n is zero or 1 ; providing that when A
represents a group of formula (a), any substituent present in Ar ortho to the carboxamide moiety is necessarily a hydrogen or a methoxy group; r and s independently represent an integer from zero to 3 such that the sum of r and s is equal to an integer from 1 to 4; and V represents a bond, O or S; and salts thereof. In the compounds of formula (I) above an alkyl group or moiety may be straight or branched. Alkyl groups which may be employed include methyl, ethyl, n- propyl, n-butyl, n-pentyl, n-hexyl and any branched isomers thereof such as isopropyl, t-butyl, sec-butyl, and the like. When R1 represents an arylC-|_4alkoxy, arylsulfonyl, arylsulfonyloxy, ary-sulfonylC-| _4alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC-|_4alkyl, arylcarboxamidoCι_4alkyl, aroyl, aroylC-|_4alkyl, or arylCi^alkanoyl group, the aryl moiety may be selected from an optionally substituted phenyl ring or an optionally substituted 5 or 6-membered heterocyclic ring. In the group R1 an aryl moiety may be optionally substituted by one or more substituents selected from hydrogen, halogen, amino, cyano, Cι_4alkyl,
Cι_4alkylamido, C^alkanoyl, or R R6NCO where each of R5 and R6 independently represents a hydrogen atom or C-| _4alkyl group. A halogen atom present in the compounds of formula (I) may be fluorine, chlorine, bromine or iodine. When q is 2, the substituents R1 may be the same or different. An optionally substituted 5- or 6-membered heterocyclic aromatic ring, as defined for any of the groups Ar, Ar1 , Ar2 or Ar3 may contain from 1 to 4 heteroatoms selected from O, N or S. When the ring contains 2-4 heteroatoms, one is preferably selected from O, N and S and the remaining heteroatoms are preferably N. Examples of 5 and 6-membered heterocyclic groups include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, oxadiazolyl, thiadiazolyl, pyridyl, triazolyl, triazinyl, pyridazyl, pyrimidinyl, pyrazolyl, isothiazolyl, and isoxazolyl. Examples of bicyclic, for example bicyclic aromatic or heteroaromatic, ring systems for Ar include naphthyl, indazolyl, indolyl, benzofuranyl, benzothienyl, benzothiazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzisothiazolyl, quinolinyl, quinoxolinyl, quinazolinyl, cinnolinyl, isoquinolinyl, pyrazolo[1 ,5-
a]pyrimidyl, pyrrolo[3,2-b]pyridyl, pyrrolo[3,2-c]pyridyl, thieno[3,2-b]thiophenyl, 1 ,2- dihydro-2-oxo-quinolinyl, 3,4-dihydro-3-oxo-2H-benzoxazinyl, 1 ,2-dihydro-2-oxo-3/-- indolyl. The rings Ar, Ar1 , or Ar2 may each independently be optionally substituted by one or more substituents selected from: a hydrogen or halogen atom, or a hydroxy, oxo, cyano, nitro, trifluoromethyl, C^alkyl, C-^alkoxy, C-|.
4alkylenedioxy, C-|_4alkanoyl, C-^alkylsulfonyl, C-|_4alkylsulfinyl, C-i^alkylthio,
R7S02N(R8)-, R7R8NSO2-, R7R8N-, R7R8NCO-, or R7CON(R8)- group wherein each of R7 and R8 independently represents a hydrogen atom or a C1.4 alkyl group, or R7R8 together form a C3.6 alkylene chain. Alternatively, Ar and Ar2 may be optionally substituted by one or more 5- or 6-membered heterocyclic rings, as defined above, optionally substituted by a C-μ2 alkyl or R7R8N- group; wherein R7 and R8 are as defined above. In the rings Ar and Ar2 substituents positioned ortho to one another may be linked to form a 5- or 6- membered ring. It will be appreciated that for use in medicine the salts of formula (I) should be physiologically acceptable. Suitable physiologically acceptable salts will be apparent to those skilled in the art and include for example acid addition salts formed with inorganic acids eg. hydrochloric, hydrobromic, sulfuric, nitric or phosphoric acid; and organic acids eg. succinic, maleic, acetic, fumaric, citric, tartaric, benzoic, p-toluenesulfonic, methanesulfonic or naphthalenesulfonic acid. Other non-physiologically acceptable salts eg. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention. Also included within the scope of the invention are solvates and hydrates of compounds of formula (I). Certain of the compounds of formula (I) may form acid addition salts with one or more equivalents of the acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms. The compounds of formula (I) can exist in the form of cis- and trans- isomers with respect to the configuration at the cyclohexyl ring. When A represents a group (c) the compounds may also exist as geometric isomers around the double bond. The present invention includes within its scope all such isomers, including mixtures. Preferably the compounds of the invention are in the trans configuration
with respect to the cyclohexyl ring. For compounds of formula (I) where A represents a group (c), trans geometry of the double bond is preferred. In compounds of formula (I), it is preferred that R1 represents a substituent selected from: a halogen atom, methyl, cyano, acetyl, trifluoromethyl, pentafluoroethyl, methylsulphonyl, methylsulphonyloxy or trifluoromethoxy group.
Alternatively, it is preferred that R1 represents a group Ar3Z, where Z is a bond and
Ar3 is a 5- or 6-membered ring heterocycle, optionally substituted by a methyl group, containing at least one N and one O atom. Preferably q is 1. R2 is preferably a hydrogen atom. When the group A is a group of formula (a), preferred examples of Ar include optionally substituted phenyl, indolyl, pyrazolo[1 ,5-a]pyrimidyl, cinnolinyl, quinolinyl, benzo[b]furanyl or pyrrolopyridyl. When the group A is a group of formula (b), preferred examples of Ar1 include optionally substituted phenyl, Y is preferably a bond, and preferred examples of Ar2 include optionally substituted phenyl, pyridyl, pyrimidinyl, isoxazolyl, oxazolyl or oxadiazolyl. When the group A is a group of formula (c), preferred examples of Ar include optionally substituted phenyl. It is also preferred that the rings Ar, Ar1 , or Ar2 are each independently optionally substituted by one or more substituents selected from: a hydrogen or halogen atom, cyano, methoxy, trifluoromethyl, methylenedioxy, acetyl, acetylamino, methylsulfonyl, methylsulfonyloxy, methylaminosulfonyl, methylsulfonylamino, or methylaminocarbonyl group. Certain of the substituted heteroaromatic ring systems included in compounds of formula (I) may exist in one or more tautomeric forms. The present invention includes within its scope all such tautomeric forms, including mixtures. Particular compounds according to the invention include those specifically exemplified and named hereinafter:
frat7s-3-(2-(1-(4-(4-Quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-
3-benzazepine; trans-( £)-3-(2-(1 -(4-(3-(3-Methylsulfonyl)phenylpropenoyl) amino) cyclohexyl) ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine;
trans-(£)-3-(2-(1-(4-(3-(4-Fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-3-(2-(1-(4-(2-lndolyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trans-3-(2-(1-(4-(3-(3-Pyridyl)phenyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-3-(2-(1-(4-Phenylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 7-3- benzazepine; trans-3-(2-(1-(4-(3-lndolyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trans-3-(2-(1-(4-(4-Quinolinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trans-(£)-3-(2-(1-(4-(3-(4-Fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-6- methoxy-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-6-Methoxy-3-(2-(1-(4-(4-quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; frans-6-Methoxy-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl)carboxamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-(3-(5-methyl)-1 ,2,4-oxadiazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(3-acetylamino)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(6-(3,4-dihydro-3-oxo)-2H-benzoxazinyl)carboxamido)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-benzazepine; ftat?s-(£)-7-Cyano-3-(2-(1-(4-(3-(6-(1 ,2-dihydro-2-oxo)quinolinyl)propenoyl)amino)- cyclohexyl) ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(2-fluoro-4-acetylamino)phenylpropenoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; fratJS-(£)-7-Cyano-3-(2-(1-(4-(3-(8-(1 ,2-dihydro-2-oxo)quinolinyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-3-(2-(1-(4-(3-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)benzoyl)amino)cyclohexyl)ethyl)-
7-methylsulphonyl-2,3,4,5-tetrahydro-1 b-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl)
carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-(£)-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(E)-7-(5-(3-Methyl)isoxazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; frans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(4-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; fta/7s-7-Cyano-3-(2-(1-(4-(2,5-difluoro)phenylacetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; traπs-(£)-7-Cyano-3-(2-(1-(4-(3-(2,4- difluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 7-3- benzazepine; frat7S-(£)-7-Cyano-3-(2-(1-(4-(3-(2,5- difluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; frat7s-7-Cyano-3-(2-(1-(4-(3-phenylpropanoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; fra/7s-(£)-7-Cyano-3-(2-(1-(4-(3-(4- methoxy)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trat7S-(£)-7-Cyano-3-(2-(1-(4-(3-(2-acetyl)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trat7S-(E)-7-Cyano-3-(2-(1-(4-(3-(4-acetyl)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; fra/ιs-(£-)-7-Cyano-3-(2-(1-(4-(3-(2-cyano)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; fraπs-(£)-7-Cyano-3-(2-(1 -(4-(3-(3-cyano)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-7-Cyano-3-(2-(1-(4-(3-(5-(3-methyl)isoxazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-(-Z)-7-Cyano-3-(2-(1-(4-(3-phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine;
trans-(£)-7-Cyano-3-(2-(1 -(4-(3-(2-pyridyl)propenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 --3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(1-(4-fluoro)naphthyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(6- benzodioxanyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(3-(5-fluoro)indolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(E)-7-Cyano-3-(2-(1-(4-(3-(3-(1-methyl)benzimidazolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(7-benzofuranyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-(£)-7-Cyano-3-(2-(1-(4-(3-(5-(3-methyl)indolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(6-(2,3-dihydro-2-oxo)indolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(2-benzofuranylacetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-(E)-7-Cyano-3-(2-(1 -(4-(3-(4-(2-methyl)indolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1 -(4-(3-(5-benzimidazolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-Cyano-3-(2-(1 -(4-(3-(2,3-methylenedioxy)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(3-(1-(2-oxo)pyrrolidinyl))phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(2-indolylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-
1 H-3-benzazepine; ttans-7-Cyano-3-(2-(1-(4-(2-benzothiophenylacetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-(3-bromo)thiophenyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(3-(2-pyridyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-(5-pyrimidinyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; tra/7s-7-Cyano-3-(2-(1-(4-(3-(4-cyanophenyl)benzoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-thiophenyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-furanyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(3-thiophenyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(3-furanyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; fraπs-(E)-7-Cyano-3-(2-(1 -(4-(3-(4-quinolinyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; ttans-(£)-7-Cyano-3-(2-(1-(4-(3-(5-pyrimidinyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trarϊs-7-Cyano-3-(2-(1-(4-(2,4-difluoro)phenylacetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trat7S-7-Cyano-3-(2-(1-(4-(6-(2-amino)benzothiazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-7-Cyano-3-(2-(1 -(4-(6-(2-methyl)benzothiazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 --3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(4-methylaminocarbonyl)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(5-(2-amino)benzoxazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; t/-ans-7-Cyano-3-(2-(1-(4-(3-(1-pyrazolyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; frans-7-Cyano-3-(2-(1-(4-(2-thiophenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-benzothiophenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine;
ttans-7-Cyano-3-(2-(1-(4-(3-(2-(5-methyl)-1 ,3,4-oxadiazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-naphthyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(E)-7-Cyano-3-(2-(1-(4-(3-(5-(3-acetyl)indolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-(5-(3-methyl)-1 ,2,4-oxadiazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 /--3-benzazepine; frat7s-7-Cyano-3-(2-(1-(4-(5-(2-methyl)benzimidazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(3-(2- acetyl)furanyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 -/-3- benzazepine; frans-7-Cyano-3-(2-(1-(4-(6-(2-amino)benzoxazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(2-benzothiophenyl)acetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-thienyl) propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 A7-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(5-quinolinyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frat7s-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1 -(4-(3-(3-(5-Methyl)-1 ,2,4- oxadiazolyl) benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1 -(4-(8-(1 ,4-dihydro-4-oxo)quinolinyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 -/-3-benzazepine; fraπs-(£)-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-acetamido-2- fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-acetyl)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine;
trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(2,4-difluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(2-naphthyl)acetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(7-(3,4-dihydro-3-oxo)-2H- benzoxazinyl)carboxamido)cycIohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; fraπs-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(2-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 7-3-benzazepine; traπs-3-(2-(1-(4-(5-(2-Methyl)quinolinyl)carboxamide)cyclohexyl)ethyl)-7- methanesulphonyloxy-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1 -(4-(2- indolyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(2-benzothiophenyl)acetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; traπs-(E)-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-thienyl) propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; ttans-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(5-quinolinyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1 -(4-(8-(1 ,4-dihydro-4-oxo)quinolinyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1 -(4-(3-(3-(5-Methyl)-1 ,2,4- oxadiazolyl) benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-(3-(5-Methyl)-1 (2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 -/-3-benzazepine; trans-(£)-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(2-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-7-(5-(3-Methyl)isoxazolyl)-3-(2-(1-(4-(2-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(3-(5-Methyl)isoxazolyl)-3-(2-(1-(4-(4-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frat?s-(£)-7-(2-(5-Methyl)oxazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine;
trans-(£)-7-(3-(5-Methyl)isoxazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-(5-Pyrimidyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trat?s-7-(5-Pyrimidinyl)-3-(2-(1 -(4-(3-(3-(5-Methyl)-1 ,2,4- oxadiazolyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(3-(5-Methyl)isoxazolyl)-3-(2-(1-(4-(5-(2-methyl)quinolinyl)carboxamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; and trans-3-(2-(1-(4-(3-(2-(5-Methyl)oxazolyl)benzoyl)amino)cyclohexyl)ethyl)-7- methylsulphonyloxy-2,3,4,5-tetrahydro-1 b-3-benzazepine.
Preferred Compounds include: traπs-7-Cyano-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl)carboxamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(2-naphthylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-
1 --3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 b-3-benzazepine; ttat7S-(£)-7-Cyano-3-(2-(1-(4-(3-(3-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 --3-benzazepine; fraπs-7-Cyano-3-(2-(1 -(4-(8-(1 ,4-dihydro-4- oxo)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(2-naphthyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(2-naphthyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(2- methoxy)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(3- methoxy)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; fra/7S-7-Cyano-3-(2-(1 -(4-(7-(1 ,2-dihydro-2- oxo)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine;
trans-7-Cyano-3-(2-(1-(4-(3-(3-(5-ethyl)-1 ,2,4-oxadiazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 /--3-benzazepine; traπs-7-Cyano-3-(2-(1-(4-(1-naphthyl)acetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; traπs-7-Cyano-3-(2-(1-(4-(6-(2,3-dihydro-2-oxo)indolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-7-Cyano-3-(2-(1-(4-(5-(2,3-dihydro-2-oxo)indolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1 -(4-(6-(1 ,2-dihydro-2- oxo)quinolinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trat7s-7-Cyano-3-(2-(1 -(4-(7-(1 ,2-dihydro-2- oxo)quinolinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trat7s-7-Cyano-3-(2-(1-(4-(6-quinoxalinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(6-(3,4-dihydro-2-oxo)-2H-benzoxazinyl)acetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-fluoro-5-acetamido)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(5-(2-methyl)quinolinyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 -/-3-benzazepine; trans-3-(2-(1-(4-(3-(2-(4-Methyl)oxazolyl)benzoyl)amino)cyclohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1 --3-benzazepine; trans-3-(2-(1-(4-(3-trifluoromethylbenzoyl)amino)cy ohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1 -/-3-benzazepine; t/-ans-7-(5-Pyrimidinyl)-3-(2-(1-(4-(5-(2- methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trans-(£)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(2-cyano)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; fraπs-(E)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(3-cyano)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; and frans-(£)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(4-cyano)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine.
Most preferred compounds include:
tra/7s-(£)-7-Cyano-3-(2-(1-(4-(5-quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 --benzazepine; trans-7-Cyano-3-(2-(1-(4-(5-(8-fluoro)quinolinyl)carboxamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-3-(2-(1-(4-(5-(2-Methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine; trat7S-3-(2-(1-(4-(5-(2-Methyl)quinolinyl)carboxamide)cyclohexyl)ethyl)-7- methanesulphonyloxy-2,3,4,5-tetrahydro-1 --3-benzazepine; frans-(£)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-3-(2-(1-(4-(5-(8-Chloro-2-methyl)quinolinyl)carboxamide)cyclohexyl)ethyl)-7- methanesulphonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine; frat7S-(£)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(E)-7-(2-Pyrimidyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; tra/7s-(£)-7-(1-Pyrrolidinylcarbonyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(1-Pyrrolidinylcarbonyl)-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trat7S-3-(2-(1-(4-(5-(8-Fluoro-2-methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1 --3-benzazepine; trans-3-(2-(1-(4-(5-(8-Fluoro-2-methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-7- methylsulphonyloxy-2,3,4,5-tetrahydro-1 H-3-benzazepine.
These compounds may be in the form of their free base or physiologically acceptable salts thereof, particularly the monohydrochloride or monomesylate salts. The present invention also provides a process for preparing compounds of formula (I) which process comprises: (a) reacting a compound of formula (II):
wherein R1 , R2 and q are as hereinbefore defined, with a compound of formula (III):
A-COX
Formula (III)
wherein A is as hereinbefore defined and X is a halogen atom or the residue of an activated ester; (b) to prepare a compound of formula (I) by reacting a compound of formula (II) with a compound A-Br, or A-l, or A-OSO2CF3 in the presence of carbon monoxide and a catalyst such as frans-b/s-triphenylphosphinepalladium(ll)bromide; (c) to prepare a compound of formula (I) wherein R1 is Ar3-Z and Z is a bond, reacting a compound of formula (IV):
Formula (IV)
wherein R2 and A are as hereinbefore defined and one R1 a represents a group W wherein W is a halogen atom or a trifluoromethylsulfonyloxy group, or W is a group M selected from a boron derivative e.g. a boronic acid function B(OH)2 or a metal function such as trialkylstannyl e.g. SnBu3, zinc halide or magnesium halide, and when q is 2 the other R1 a is R1 ; with a compound Ar3-W^ , wherein W1 is a halogen atom or a trifluoromethylsulfonyloxy group when W is a group M or W1 is a group M when W is a halogen atom or a trifluoromethylsulfonyloxy group; (d) to prepare a compound of formula (I) wherein R^ is f\β-Z and Z is O or S, reacting a compound of formula (V):
Formula (V)
wherein R2 and A are as hereinbefore defined and one R1 D represents a group ZH and when q is 2 the other R1 D represents R1 ; with a reagent serving to introduce the group Ar3; (e) to prepare a compound of formula (I) where Y is a bond, reaction of a compound of formula (VI):
wherein R^ , R2, Ar^ , W and q are as hereinbefore defined, with a compound Ar2-
W^ , wherein W is a halogen atom or a trifluoromethylsulfonyloxy group when W is a group M, or W1 is a group M when W is a halogen atom or a trifluoromethylsulfonyloxy group. (f) interconversion of one compound of formula (I) to a different compound of formula (I) e.g. (i) alkylation of a compound (I) wherein R2 represents hydrogen,
(ii) conversion of one R1 from alkoxy (e.g.methoxy) to hydroxy, or (iii) conversion of
R1 from hydroxy to sulfonyloxy, eg alkylsulfonyloxy or trifluoromethanesulfonyloxy; (iv) conversion of a compound wherein Y represents S to a compound wherein Y is S02 or (v) conversion of Y from CO to CH ; (g) separation of cis- and trans- isomers of compounds of formula (I) by conventional methods, e.g. chromatography or crystallisation; and optionally thereafter forming a salt of formula (I).
Process (a) may be effected using conventional methods for the formation of an amide bond. When X is the residue of an activated ester this may be formed with e.g. a carbodiimide such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide. The reaction may be carried out in a solvent such as dichloromethane. Reaction of a compound of formula (IV) with Ar3W1 , according to process
(c) or a compound of formula (VI) with Ar2-W1 according to process (e) may be effected in the presence of a transition metal eg palladium catalyst such as bis- triphenylphosphinepalladium dichloride or tetra/ /s-triphenylphosphinepalladium (0). When M represents a boronic acid function such as B(OH)2the reaction may be carried out under basic conditions, for example using aqueous sodium carbonate in a suitable solvent such as dioxane. When M is trialkylstannyl the reaction may be carried out in an inert solvent, such as xylene or dioxane optionally in the presence of LiCI. When M is a zinc or magnesium halide the reaction may be effected in an aprotic solvent such as tetrahydrofuran. The substituent W is preferably a halogen atom such as bromine, or a sulfonyloxy group such as trifluoromethylsulfonyloxy; and W^ is preferably a group M, such as trialkylstannyl or B(OH)2. In process (d) the reagent serving to introduce the group Ar3 is preferably a compound of formula Ar3-Hal, wherein Hal is a halogen atom. The reaction may be effected in the presence of a base, such as potassium carbonate, in a solvent such as dimethylformamide. Interconversion reactions according to process (f) may be effected using methods well known in the art. Compounds of formula (II) may be prepared by conversion of a compound of formula (VII), wherein R^ and q are as hereinbefore defined,
into a corresponding ketone, followed by reductive amination. This may be effected by methods well known in the art for (i) conversion of a ketal to a ketone in the
presence of aqueous acid; followed by (ii) reductive amination of the ketone with
R2NH2 or ammonium acetate in the presence of a reducing agent. Suitable reducing agents which may be employed include sodium borohydride, cyanoborohydride or triacetoxyborohydride under acidic conditions, or catalytic hydrogenation. The reaction may conveniently be effected in a solvent such as methanol, ethanol or dichloroethane. A compound of formula (VII) may itself be prepared by reacting a compound of formula (VIII):
Formula (VIM)
wherein R1 and q are as hereinbefore defined; with a compound of formula (IX):
in the presence of a reducing agent. Suitable reducing agents which may be employed include sodium borohydride, cyanoborohydride or triacetoxyborohydride under acidic conditions, or catalytic hydrogenation. The reaction may conveniently be effected in a solvent such as ethanol or dichloroethane. The individual cis- and trans- isomers of a compound of formula (II) may be prepared starting from c/?s- or trans- 4-amino-cyclohexaneacetic acid (T.P. Johnson, et al., J. Med. Chem., 1997, (20), 279-290) followed by functional group interchange and/or protection using methods well known in the art, to give the individual cis- or trans- isomers of a compound of formula (X):
Formula (X)
wherein R2 is as hereinbefore defined, and P is a protecting group, for example trifluoroacetyl or tert-butoxycarbonyl. Subsequent reaction of a compound of formula (X) with a compound of formula (VIII) in the presence of a reducing agent as described above followed by deprotection using standard methodology gives the individual isomers of a compound of formula (II) wherein R2 is as hereinbefore defined. Compounds of formula (III) are known or may be prepared using standard procedures. Compounds of formula (IV), (V) or (VI) may be prepared by processes analogous to (a), (b), (c) and (d) described above. Compounds Ar2W1 , Ar^W and
Ar3Hal are commercially available or may be prepared by standard methods.
Compounds of formula (VIM), where for example R1 is a halogen, methoxy, acetyl, cyano, carboxylic acid or carboxamide group are known in the literature or may be prepared by known methods. The compound of formula (IX) is likewise known in the literature. Conversion of a compound of formula (VIII) where R1 is a cyano or acetyl group to a compound of formula (VIII) where R1 is a group Ar3Z, where Ar is an oxadiazole or an isoxazole ring and Z is a bond, may be carried out by (i) conversion to a compound of formula (XI), where R^ and q are as hereinbefore defined, using standard methods; (ii) conversion of R1 from cyano to oxadiazolyl using known methods, or conversion of acetyl to isoxazolyl using known methods; (iii) deprotection of a compound of formula (XI) to a compound of formula (VIII) using standard methods.
Description 1 2,3,4,5-Tetrahydro-1H-3-benzazepine
1 ,2-Phenylenediacetonitrile (7.5g, 48 mmol) dissolved in ethanol (150ml) was added to Raney Ni (2g) which had been previously washed with ethanol (3x20ml). The mixture was then hydrogenated at 50°C at 50psi pressure with shaking for 24h. The reaction mixture was then cooled to room temperature and filtered through a pad of kieselguhr and washed through with ethanol (100ml). The filtrate was evaporated in vacuo to give a brown oil which was chromatographed on silica gel (100g), eluting with 2-10% methanol in CH2CI2 to give the title compound as a brown oil (2.45g, 35%).
Mass spectrum (API+) Found: 148 (MH+). C10H-13N requires 147.
Description 2 frans-3-(2-(1-(4-(/V-te/ -Butoxycarbonyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 A -3-benzazepine
Sodium triacetoxyborohydride (4.3g, 20.4 mmol) was added to a mixture of 2,3,4,5-tetrahydro-1 H-3-benzazepine (2.0g, 13.6 mmol), and fraπs-2-(1-(4- (N-fe/t-butoxycarbonyl)amino)cyclohexyl)acetaldehyde in 1 ,2-dichloroethane (200ml), and the mixture stirred at room temperature for 0.5h. The reaction mixture was diluted with CH2CI2 (100ml) and washed with saturated aqueous K2CO3 (200ml), followed by brine (100ml). The organic layer was separated and dried over Na2SO4, then evaporated in vacuo to give an off- white solid which was chromatographed on silica gel eluting with ethyl acetate to give the title compound as an off-white solid (3.13g, 62%).
Mass spectrum (API+): Found 373. C23H3βN2O2 requires 372.
The following compound was prepared in a similar manner to Description 2 (a) frans-3-(2-(1-(4-Λ^tert-Butoxycarbonyl)amino)cyclohexyl)ethyl-6- methoxy-2,3,4,5-tetrahydro-1H-3-benzazapine
Mass spectrum (API+): Found 403 (MH+). C24H38N2O3 requires 402.
b) fraπ*-3-(2-(1-(4-/V--ferf-Butyloxycarbonyl)amino)cyclohexyl)ethyl-7-cyano- 2,3,4,5-tetrahydro-1 H-3-benzazepine
Mass spectrum (API+) Found 398 (MH+). C2 H35N302 requires 397.
1 H NMR (CDCI3) δ: 0.97 - 1.13 (4H, m), 1.22 (1 H, m), 1.36 - 1.47 (11 H, m), 1.71 -
1.79 (2H, m), 1.95 - 2.04 (2H, m), 2.48 (2H, m), 2.61 (4H, m), 2.90 - 3.00 (4H, m), 3.37 (1 H, m), 4.35 (1 H, m), 7.17 (1 H, d, J = 5 Hz), 7.36 (1 H, s), 7.52 (1 H, d, J = 5 Hz).
Description 3 frans^3-(2-(1-(4-Amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine
A mixture of frans-2-(2-(1-(4-(/\/-tert-butoxcarbonyl)amino)cyclohexyl)ethyl)- 2,3,4,5-tetrahydro-1 H-3-benzazepine (3.1 g, 8.3 mmol) and trifluoroacetic acid (5ml) in CH2CI2 (50ml) was stirred at room temperature for 1 h, then at
40°C for 1 h. The reaction mixture was then diluted with CH2CI2 (100ml) and washed with saturated aqueous K2Cθ3 (2x100ml). The organic layer was dried over Na SO4 and evaporated in vacuo to give the title compound as a brown oil (2.14g, 95%).
Mass spectrum (API+): Found 273 (MH+). C-|8H28N2 requires 272.
The following compound was prepared in a similar manner to Description 3
(a) frans-3-(2-(1-(4-Amino)cyclohexyl)ethyl)-6-methoxy-2,3,4,5- tetrahydro-1 H-3-benzazepine
Mass spectrum (API+): Found 303 (MH+). C-|gH3oN O requires 302. b) frans-3-(2-(1 -(4-Amino)cyclohexyl)ethyl)-7-cyano-2,3,4,5-tetrahydro-1 H-3- benzazepine
Mass spectrum (API+): Found 298 (MH+). C-| gH 7N3 requires 297.
1 H NMR (CDCI3) δ: 0.92 - 1.18 (6H, m), 1.21 (1 H, m), 1.41 (2H, m), 1.75
(2H, m), 1.85 (2H, m), 2.49 (2H, m), 2.60 (5H, m), 2.95 (4H, m), 7.16 (1 H, d, J = 5 Hz), 7.36 (1 H, s), 7.40 (1 H, d, J = 5 Hz).
Description 4
trans-2-(Λ-(4-(N- ferf-Butyloxycarbonyl)amino)cyclohexyl)acetic acid, methyl ester
A mixture of trans-(4-amino)cyclohexylactic acid hydrogen sulfate (T.P. Johnston et at, J. Med Chem., 1977, 20 (2), 279-290), (27.0g, 106mmol), cone. H2SO4 (3ml), and methanol (300ml) was stirred at reflux for 5h. Resulting solution was filtered and the filtrate evaporated in vacuo to give a brown oil (36g). A mixture of this material, triethylamine (36ml; 26.1 g, 259 mmol), dichloromethane (600ml) and di-f- butyl dicarbonate (25.5g, 117mmol) was stirred at 20°C for 18h. Resulting solution was partitioned between saturated aqueous NaHCO3 (500ml) and dichloromethane (3x200ml), and the combined extracts were dried (Na2SO4) and evaporated in vacuo to give the title compound (24.6g, 86%) as a colourless solid. 1H NMR (CDCI3) δ: 1.08 (4H, m), 1.43 (9H, s), 1.76 (3H, m), 2.00 (2H, m), 2.20 (2H, d, J = 7 Hz), 3.37 (1 H, m), 3.66 (3H, s), 4.39 (1 H, br s).
Description 5 fra/7S-2-(1-(4-(/v-fert-Butyloxycarbonyl)amino)cyclohexyl)acetaldehyde
To a stirred solution of trans-2-{\-{4-{N-tert- butyloxycarbonyl)amino)cyclohexyl)acetic acid, methyl ester (46.0g, 170 mmol) in dry toluene (920ml) at -78°C under argon was added a solution of di- isobutylaluminium hydride (1 M; 285 ml; 285 mmol), dropwise over 0.5h. Resulting solution was stirred for a further 0.3h and quenched with a mixture of methanol (28ml) in toluene (50ml) and then poured into saturated aqueous potassium sodium tartrate (1.2L). The resultant mixture was extracted with ether (4x1 L). The combined organic extracts were dried (Na2SO4) and evaporated in vacuo to give a waxy solid which was purified using silica gel, eluting with 10-50% ethyl acetate/hexane to give the title compound (21.77g, 53%) as a colourless solid. 1H NMR (CDCI3) δ: 1.12 (4H, m), 1.44 (9H, s), 1.78 (3H, m), 2.00 (2H, m), 2.33 (2H, dd, J = 7, 2 Hz), 3.37 (1 H, m), 4.40 (1H, m), 9.75 (1 H, m).
Description 6
7-Hydroxy-2,3,4,5-tetrahydro-1 H-3-benzazepine, hydrobromide
7-Methoxy-2,3,4,5-tetrahydro-1 H-3-benzazepine (10 g) in 48% aqueous hydrobromic acid (350 ml) was allowed to stir at 100 °C for 4 h. The mixture was cooled to 20 °C then evaporated to dryness in vacuo to give the title compound (14.5 g) as a brown solid.
Mass spectrum (API+): Found 164 (MH+). C10H13NO requires 163.
1 H NMR (DMSO) δ: 2.80 - 3.25 (8H, m), 4.42 (2H, br s), 6.50 - 6.70 (2H, m), 6.98 (1 H, d, J = 8 Hz), 8.86 (1 H, br s).
Description 7 3-(fert-Butyloxycarbonyl)-7-hydroxy-2,3,4,5-tetrahydro-1H-3-benzazepine
To a solution of 7-hydroxy-2,3,4,5-tetrahydro-1 H-3-benzazepine, hydrobromide (14.5 g) in tetrahydrofuran (100 ml) and water (70 ml), was added triethylamine (8 g), followed by a solution of di-tetf-butyl dicarbonate (14 g) in THF (20 ml). The resulting mixture was allowed to stir at 20 °C for 16 h, partitioned between ethyl acetate (200 ml) and water (200 ml). The aqueous layer was washed with ethyl acetate (100 ml). The combined organic extracts were washed with saturated aqueous sodium bicarbonate (100 ml), dried (Na2SO4) and evaporated to dryness in vacuo. The resulting oil was purified by silica gel chromatography. Elution with ethyl acetate in hexane (10% - 30%) gave the title compound (8 g).
Mass spectrum (API+): Found 164 (MH+-Boc). C-|5H2-| Nθ3 requires 263.
1 H NMR (CDCI3) δ: 1.48 (9H, s), 2.75 - 2.87 (4H, m), 3.40 - 3.60 (4H, m), 4.95
(1 H, s), 6.50 - 6.62 (2H, m), 6.96 (1 H, d, J = 8 Hz).
Description 8
3-(te/ -Butyloxycarbonyl)-7-trifluoromethylsulfonyloxy-2,3,4,5-tetrahydro-1 W-
3-benzazepine
To a stirred mixture of 3-(te/?-butyloxycarbonyl)-7-hydroxy-2,3,4,5-tetrahydro-1 A7-3- benzazepine (7 g) and triethylamine (5.4 ml) in dry dichloromethane under argon at -20 °C, was added, dropwise, trifluoromethanesulfonic anhydride (5 ml). The resulting mixture was allowed to warm slowly to 20 °C over 16 h, then was poured into saturated aqueous sodium bicarbonate (200 ml) and extracted with dichloromethane (2 x 150 ml). The combined organic extracts were washed with brine (150 ml), dried (Na2SO4) and evaporated in vacuo to give an amber oil.
Silica gel chromatography, eluting with ethyl acetate in hexane (10% - 30%) gave the title compound (7 g) as an amber oil.
Mass spectrum (API+): Found 396 (MH+). Ci6H20 3NO5S requires 395.
1 H NMR (CDCI3) δ: 1.48 (9H, s), 2.85 - 2.95 (4H, m), 3.5 - 3.65 (4H, m), 7.00 - 7.05 (2H, m), 7.15 - 7.27 (1 H, m).
Description 9 3-(tert-Butyloxycarbonyl)-7-cyano-2,3,4,5-tetrahydro-1 H-3-benzazepine
A mixture of 3-(te/?-butoxycarbonyl)-7-trifluoromethylsulfonyloxy-2,3,4,5-tetrahydro- 1 H-3-benzazepine (4.78 g, 12.1 mmol), zinc cyanide (1.42 g, 15.6 mmol) and tetrakis- triphenylphosphine palladium (0) (1.4 g, 1.2 mmol, 10 mol%), in dry dimethylformamide (50ml) was stirred at 100 °C for 3 h under argon. After cooling to room temperature the reaction mixture was diluted with ethyl acetate (120 ml) and filtered. The filtrate was washed with saturated aqueous sodium bicarbonate (100 ml), then water (2 x 50 ml), then brine (50 ml). The organic layer was dried over sodium sulfate and evaporated in vacuo to give brown oil, which was purified by chromatography on silica gel with 20 - 100% ethyl acetate - hexane elution to give the title compound (0.765 g, 23%) as a brown oil.
Mass spectrum (API+): Found 173 (MH+-Boc). CiβH2oN202 requires 272.
1 H NMR (CDCI3) δ: 1.47 (9H, s), 2.93 (4H, m), 3.56 (4H, m), 7.21 (1 H, d, J = 8 Hz), 7.42 (2H, m).
Description 10 7-Cyano-2,3,4,5-tetrahydro-1H-3-benzazepine
A mixture of 3-(tert-butoxycarbonyl)-7-cyano-2,3,4,5-tetrahydro-1 H-3-benzazepine (765 mg, 2.81 mmol) and trifluoroacetic acid (2 ml), in dichloromethane (20 ml) was stirred at 40 °C for 1 h. The reaction mixture was evaporated to dryness in vacuo and partitioned between ethyl acetate (50 ml) and water (50 ml). The aqueous layer was basified using potassium carbonate and re-extracted with ethyl acetate (2 x 30ml). The combined basic organic extracts were dried over sodium sulfate and evaporated in vacuo to give the title compound as a colourless oil (212 mg, 44%).
Mass spectrum (API+): Found 173 (MH+). C-n H-| 2N2 requires 172.
1 H NMR (CDCI3) δ: 2.04 (1 H, br s), 2.95 (8H, m), 7.18 (1 H, d, J = 8 Hz), 7.38 (2H, m).
Description 11
3-(3-Bromophenyl)-5-methyl-1,2,4-oxadiazole
Potassium terf-butoxide (7.33 g, 65.4 mmol) was added over 5 minutes to ice chilled, stirred methanol under argon. After a further 5 min hydroxylamine hydrochloride (4.9 g, 70.43 mmol) was added in one portion and the resultant mixture stirred at room temperature for 1 h. A solution of 3-bromobenzonitrile (7.93 g, 43.6 mmol) in methanol (120 ml) was added in one portion and the mixture heated at reflux for 4 h, cooled filtered, and the filtrate evaporated in vacuo. The residue was refluxed in acetic anhydride (60 ml) for 3 h, cooled to room temperature and poured into ice-water (300 ml). The precipitate was filtered, washed with water, dried in vacuo and chromatographed on silica eluting with 0 - 10% ethyl acetate - hexane gradient. Fractions containing desired product were pooled and evaporated in vacuo and the residue recrystallised from hexane to afford the title compound as colourless crystals (5.2 g, 50 %).
Mass spectrum: (API+) Found: 239 (MH+). C9H7 79BrN2O requires 238
1 H NMR (CDCI3) δ: 2.66 (3H, s), 7.36 (1 H, t, J = 8 Hz), 7.63 (1 H, m), 8.05 (1 H, m), 8.23 (1 H, m).
Description 12
3-(5-Methyl-1 ,2,4-oxadiazol-3-yl)-benzoic acid
A mixture of 3-(3-bromophenyl)-5-methyl-1 ,2,4-oxadiazole (2.68 g, 11.3 mmol), tributylamine (3.05 ml, 12.5 mmol) and trans- dibromobis(triphenylphosphine)palladium (II) (0.13 g, 0.16 mmol) in methanol (5 ml) was carbonylated at 30 psi and 100 °C for 18 h. The mixture was cooled to room temperature, diluted with ethyl acetate (100 ml) and washed sequentially with saturated sodium hydrogen carbonate (2 x 300 ml), brine (100 ml), 0.5 N hydrochloric acid (200 ml), brine (100 ml), then dried Na2SO4) and evaporated in vacuo to afford a yellow oil (2.49 g). A 2 g sample of this oil was dissolved in aqueous methanol (5:3, 80 ml), sodium hydroxide (0.36 g) added and the mixture stirred at room temperature for 20 h. The mixture was evaporated in vacuo and the residue partitioned between ethyl acetate (100 ml) and water (100 ml). The aqueous layer was acidified with 2N HCI and the resultant precipitate filtered, washed with water and dried in vacuo to afford the title compound as a colourless solid (0.78 g, 42 %).
Mass spectrum: (API+) Found: 205 (MH+). CI QH8N2O3 requires 204.
1 H NMR (CDCI3) δ: 2.70 (3H, s), 7.71 (1 H, m), 8.14 (1 H, dd, J = 7,1 Hz), 8.23 (1 H, dd, J = 7, 1 Hz), 8.54 (1 H, m), 13.35 (1 H, br s).
Description 13 3-(1-Pyrazolyl)-benzoic acid
A mixture of 3-hydrazinobenzoic acid (1.52 g, 0.01 mmol) and malondialdehydebis(dimethylacetal) (2.39 ml; 0.01 mol) in ethanol (10 ml) and water (15 ml) was heated at reflux for 2 h. The resulting solution was cooled and evaporated to afford the title product (1.8 g,; 96 %) as a yellow solid.
1 H NMR (DMSO-d6) δ: 6.60 (1 H, t, J = 2 Hz), 7.65 (1 H, t, J = 8 Hz), 7.81 (1 H, d, J =
1.5 Hz), 7.89 (1 H, dd, J = 8 and 1.5 Hz), 8.12 (1 H, dd, J = 8 and 1.5 Hz), 8.4 (1 H, d, J = 2 Hz), 8.64 (1 H, d, J = 2 Hz).
Mass spectrum (API+): Found 189 (MH+). C-| QH8N202 requires 188.
Description 14
3-(tert-Butoxycarbonyl)-7-(3-(5-methyl)-1,2,4-oxadiazolyl)-2,3,4,5-tetrahydro- 1 H-3-benzazepine
To a suspension of sodium methoxide (0.6 g, 11 mmol) in anhydrous methanol (12ml) under argon, was added hydroxylamine hydrochloride (0.76 g, 11 mmol), followed by 3-(tert-butyloxycarbonyl)-7-cyano-2,3,4,5-tetrahydro-1 A7-3-benzazepine (1.5 g, 5.5 mmol). The mixture was stirred under reflux for 16 h, then allowed to cool to room temperature. The methanol was evaporated in vacuo and the resulting residue partitioned between dichloromethane (100 ml) and water (100 ml). The aqueous layer was washed with more CH2CI2 (100 ml). The combined organic extracts were dried and evaporated in vacuo to give a solid (1.8 g), which was mixed with acetic anhydride (15 ml) and heated at 120 °C for 2 h. Excess acetic anhydride was evaporated in vacuo and the resulting oily residue partitioned between CH2CI2 (250 ml) and saturated sodium bicarbonate solution (250 ml). The organic layer was washed with more bicarbonate solution (200 ml), dried, and evaporated to give an oil. Gravity silica gel chromatography eluting with ethyl acetate in hexane gave the title compound (3.2 g, 73 %) as a colourless oil. 1H NMR (CDCI3) δ: 1.49 (9H, s), 2.65 (3H, s), 2.96 (4H, m), 3.58 (4H, m), 7.22 (1 H, d, J = 8 Hz), 7.80 (2H, m).
Description 15 7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
A solution of 3-(tert-butoxycarbonyl)-7-(3-(5-methyl)-1 ,2,4-oxadiazolyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine (1.2 g, 3.6 mmol) in CH2CI2 (15 ml) and trifluoroacetic acid (15 ml) was heater under reflux for 2 h. Solvent was evaporated in vacuo and the residue partitioned between diethyl ether (50 ml) and water (50 ml). The aqueous layer was saturated with potassium carbonate then extracted with CH2CI2
(2 x 100 ml). The combined organic extracts were dried and evaporated in vacuo to give the title compound (0.74 g, 88 %) as an oil.
Mass spectrum (API+): Found 230 (MH+). Cι3H15N3O requires 229. H NMR (CDCI3) δ: 1.80 (1 H, br s), 2.65 (3H, s), 2.90 - 3.00 (8H, m), 7.20 (1 H, d, J
= 8 Hz), 7.75 - 7.85 (2H, m).
Description 16 7-(3-(fert-Butoxycarbonyl)-2,3,4,5-tetrahydro-1W-3-benzazepinyl)carboxamide
To a solution of 3-te/f-butyloxycarbonyl)-7-cyano-2,3,4,5-tetrahydro-1 H-3- benzazepine (5.44 g, 20 mmol) cooled in ice bath, was added potassium carbonate (0.4 g) in water (1 ml), followed by dropwise addition of 30 % w/w hydrogen peroxide (2.4 ml). The resulting mixture was stirred at 5 °C for 5 min, then the ice- bath was removed. After another 5 min, water (100 ml) was added. The solid precipitate was collected by filtration and dried to give the title compound (4.35 g, 75 %) as a colourless solid.
1H NMR (CDCI3) δ: 1.48 (9H, s), 2.96 (4H, m), 3.56 (4H, m), 5.60 - 6.30 (2H, br d), 7.19 (1 H, d, J = 8 Hz), 7.50 - 7.80 (2H, m).
Description 17
3-(-rert-Butoxycarbonyl)-7-(5-(3-methyl)-1,2,4-oxadiazolyl)-2,3,4,5-tetrahydro- 1 H-3-benzazepine
A mixture of 7-(3-tert-butoxycarbonyl)-2,3,4,5-tetrahydro-1 H-3- benzazepinyl)carboxamide (4.29 g, 14.8 mmol) and Λ/,Λ/-dimethyl acetamide dimethyl acetal (6 ml, 41 mmol) was heated at 125 °C under argon. Methanol was removed from the reaction by means of a distillation condenser over 2 h. The reaction mixture was further evaporated in vacuo to give a thick brown oily residue. To this residue was added, in order, dioxan (10 ml), 5M sodium hydroxide (4 ml), hydroxylamine hydrochloride (1.4 g, 20 mmol) and 70 % aqueous acetic acid (20
ml). The combined mixture was allowed to stir at room temperature for 15 min and then at 90 °C for 1 h. The mixture was treated with water (100 ml) and extracted with CH2CI2 (2x150 ml). Combined organic extracts were washed with saturated sodium bicarbonate (100 ml), dried and evaporated in vacuo to give an oil. Gravity silica gel chromatography, eluting with ethyl acetate in hexane, gave the title compound (3.9 g, 80 %) as a colourless solid.
1H NMR (CDCI3) δ: 1.49 (9H, s), 2.47 (3H, s), 2.98 (4H, m), 3.60 (4H, m), 7.27 (1 H, d, J = 8 Hz), 7.80 - 7.90 (2H, m).
Description 18 7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine
A solution of 3-(te/f-butoxycarbonyl)-7-(5-(3-methyl)-1 ,2,4-oxadiazolyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine (3.8 g, 11.6 mmol) in CH2CI2 (50 ml) and trifluoroacetic acid (12 ml) was heated under reflux for 2 h. Solvent was evaporated in vacuo and the residue partitioned between diethyl ether (200 ml) and water (200 ml). The aqueous layer was saturated with potassium carbonate then extracted with CH2CI2 (3 x 200 ml). The combined organic extracts were dried and evaporated in vacuo to give the title compound (2.4 g, 91 %) as a colourless solid. Mass spectrum (API+): Found 230 (MH+). C13H15N3O requires 229. 1H NMR (CDCI3) δ: 1.86 (1 H, br s), 2.47 (3H, s), 3.00 (8H, ), 7.25 (1 H, d, J = 8 Hz), 7.80 - 7.90 (2H, m).
Description 19 frans-3-(2-(1-(4-/V-fert-Butyloxycarbonyl)amino)cyclohexyl)ethyl-7-(3-(5- methyl)-1 ,2,4-oxadiazolyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine
Prepared from 7-(3-(5-methyl)-1 ,2,4-oxadiazolyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine in a manner similar to Description 2, in 96 % yield.
Mass spectrum (API+): Found 455 (MH+). C26H38N4O3 requires 454.
1H NMR (CDCI3) δ: 0.90 - 1.10 (4H, m), 1.15 - 1.25 (1 H, m), 1.38 - 1.47 (11 H, m),
1.73 - 1.85 (2H, m), 1.93 - 2.05 (2H, m), 2.40 - 2.55 (2H, m), 2.56 - 2.70 (7H, m),
2.90 - 3.05 (4H, m), 3.35 (1 H, br s), 4.35 (1 H, br s), 7.19 (1 H, d, J = 8 Hz), 7.75 -
7.85 (2H, m).
Description 20
frans-3-(2-(1-(4-/V-fert-Butyoxycarbonyl)amino)cy ohexyl)ethyl-7-(5-(3- methyl)-1 ,2,4-oxadiazolyl)-2,3,4,5-tetrahydro-1 H- 3-benzazepine
Prepared from 7-(5-(3-methyl)-1 ,2,4-oxadiazolyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine in a manner similar to Description 2, in 94 % yield.
Mass spectrum (API+): Found 455 (MH+). C 6H38N O3 requires 454.
1H NMR (CDCI3) δ: 0.95 - 1.10 (4H, m), 1.23 (1 H, br s), 1.40 - 1.50 (11 H, m), 1.70 -
1.85 (2H, m), 1.95 - 2.10 (2H, m), 2.46 (3H, s), 2.46 - 2.52 (2H, m), 2.60 - 2.70 (4H, m), 2.90 - 3.60 (4H, m), 3.35 (1 H, m), 4.35 (1 H, m), 7.23 (1 H, d, J = 8 Hz), 7.80 -
7.90 (2H, m).
Description 21 frans-3-(2-(1-(4-Amino)cyclohexyl)ethyl)-7-(3-(5-methyl)-1,2,4-oxadiazolyl)-
2,3,4,5-tetrahydro-1H-3-benzazepine
Prepared from trans-3-(2-(1 -(4-Λ/-tert-butyloxycarbonyl)amino)cyclohexyl)ethyl-7-(3-
(5-methyl)-1 ,2,4-oxadiazolyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine in a manner similar to Description 3, in 100 % yield.
Mass spectrum (API+): found 355 (MH+). C2ιH30N4O requires 354.
1H NMR (CDCI3) δ: 0.90 - 1.10 (4H, m), 1.40 (2H, br s), 1.12 - 1.25 (1 H, m), 1.40 -
1.50 (2H, m), 1.70 - 1.80 (2H, m), 1.80 - 1.90 (2H, m), 2.40 - 2.50 (2H, m), 2.55 -
2.70 (8H, m), 2.90 - 3.00 (4H, m), 7.19 (1 H, d, J = 8 Hz), 7.75 - 7.85 (2H, m).
Description 22 fraπs-3-(2-(1-(4-Amino)cyclohexyl)ethyl)-7-(5-(3-methyl)-1,2,4-oxadiazolyl)-
2,3,4,5-tetrahydro-1H-3-benzazepine
Prepared from trans-3-(2-(1 -(4-Λ/-terf-butyloxycarbonyl)amino)cyclohexyl)ethyl-7-(5-
(3-methyl)-1 ,2,4-oxadiazolyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine in a manner similar to Description 3, in 100 % yield.
Mass spectrum (API+): Found 355 (MH+). C2ιH30N4O requires 354.
1H NMR (CDCI3) δ: 0.90 - 1.30 (5H, m), 1.37 - 1.50 (2H, m), 1.64 (2H, br s), 1.70 -
1.95 (4H, m), 2.46 (3H, s), 2.46 - 2.70 (7H, m), 2.90 - 3.10 (4H, m), 7.24 (1 H, d, J =
8 Hz), 7.80 - 7.90 (2H, m).
Description 23 3-Acetyl-2,3,4,5-tetrahydro-1W-3-benzazepine
A solution of acetic anhydride (6.37 g, 0.062 mol) in dichloromethane (50 ml) was added dropwise to a stirred solution of 2,3,4,5-tetrahydro-1 H-3-benzazepine (8.35 g, 0.057 mol) and triethylamine (8.7 ml) in dichloromethane (50 ml) at 0 °C under argon. After stirring at room temperature for 18 h, water (80 ml) was added and the organic layer separated. The organic layer was washed with 0.5 M hydrochloric acid (50 ml), saturated sodium bicarbonate solution (50 ml), water (50 ml) and then dried (Na2S0 ). Evaporation of the solvent in vacuo gave the title compound (10.24 g, 95 %) as a yellow oil which solidified on standing.
1 H NMR (CDCI3) δ: 2.18 (3H, s), 2.85 - 3.00 (4H, m), 3.55 - 3.60 (2H, m), 3.72 -
3.80 (2H ,m), 7.10 - 7.20 (4H, m).
Mass Spectrum AP+: Found 190 (MH+). C-|2Hι5NO requires 189.
Description 24 3-Acetyl-7-chlorosulphonyl-2,3,4,5-tetrahydro-1H-3-benzazepine
A solution of 3-acetyl-2,3,4,5-tetrahydro-1 H-3-benzazepine (4.0 g, 0.021 mol) in dichloromethane (25 ml) was added dropwise to a stirred solution of chlorosulphonic acid in dichloromethane (25 ml) at -70 °C under argon. After warming to room temperature, the reaction was stirred for 18 h before being quenched in ice/water (200 ml). The resulting mixture was extracted with ethyl acetate (3 x 100 ml), dried (Na2SO4) and the solvent evaporated in vacuo to give the title compound (2.74 g, 45 %) as a pale yellow solid.
1 H NMR: δ (CDCI3): 2.21 (3H, s), 3.0 - 3.10 (4H, m), 3.60 - 3.70 (2H, m), 3.74 -
3.80 (2H, m), 7.35 - 7.40 (1 H, m), 7.80 - 7.85 (2H, m).
Mass spectrum AP+: Found 288 & 290 (MH+). C12H-| NSO2CI requires 287 &
289.
Description 25 3-Acetyl-7-methylsulphonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine
To a stirred solution of sodium sulphite (1.60 g, 12. 6 mmol) and sodium hydrogen carbonate (1.14 g, 13.56 mmol) in water (25 ml) was added 7-3-acetyl-7- chlorosulfonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine (2.6 g, 9.04 mmol) in tetrahydrofuran (10 ml). The reaction mixture was then heated at 75 °C for 2 h, cooled to 30 °C and methyl iodide (2.8 ml, 45.20 mmol) added. After stirring at 50
°C for 24 h, the reaction mixture was cooled to room temperature and partitioned
between water (50 ml) and ethyl acetate (100 ml). The aqueous layer was then separated and further extracted with ethyl acetate (2 x 80 ml). The combined organics were then dried (Na2SO4) and the solvent removed in vacuo to give the title compound (1.77 g, 73 %) as a pale yellow solid.
1 H NMR (CDCI3) 2.20 (3H, s), 2.99 - 3.05 (4H, m), 3.06 (3H, s), 3.61 - 3.64 (2H, m), 3.73 - 3.77 (2H, m), 7.32 - 7.37 (1 H, m), 7.7 - 7.75 (2H, m).
Mass Spectrum AP+: Found 268 (MH+). C13H17NSO3 requires 267.
Description 26 7-Methylsulphonyl-2,3,4,5-tetrahydro-1H-3-benzazepine
A solution of 3-acetyl-7-methylsulphonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine (1.75 g, 6.55 mmol) in 5 M hydrochloric acid was heated at reflux for 18 h. The reaction mixture was then cooled to room temperature, basified to pH = 12 with potassium carbonate and the solvent evaporated in vacuo. The solid residue was then extracted with ethyl acetate (5 x 60 ml) and the combined organics dried (Na2Sθ4).
The solvent was then evaporated in vacuo to give the title compound (450 mg, 32 %) as a pale yellow oil.
1 H NMR (CDCI3) 1.88 (1 H, br s), 2.95 - 3.13 (8H, m), 3.04 (3H, s), 7.25 - 7.30 (1 H, d), 7.65 - 7.72 (2H, m).
Mass Spectrum AP+: Found 226 (MH+). C-| - H-|5NSO2 requires 225.
Description 27 fra/ιs-3-(2-(1-(4-(N-tert-Butyloxycarbonyl)amino)cyclohexyl)ethyl-7- methylsulphonyl-2,3,4,5-tetrahydro-1H-3-benzazepine
A solution of 7-methylsulphonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine (1.0 g, 4.67 mmol) and trans-(1-(4-Λ/-tert-butyloxycarbonyl)amino)cyclohexylacetaldehyde (0.8 g, 3.34 mmol) in dichloroethane (20 ml) was stirred at room temperature for 5 min before sodium triacetoxyborohydride (0.95 g, 4.49 mmol) was added in a single portion. After stirring at room temperature for 48 h, the reaction mixture was partitioned between water (50 ml) and dichloromethane (100 ml). The aqueous layer was separate, re-extracted with dichloromethane (2 x 50 ml) and the combined organic layers dried (Na SO4). The solvent was then removed in vacuo to give a pale yellow solid which was purified by column chromatography (silica gel;
ethyl acetate : methanol; 9 : 1) to give the title compound (1.35 g, 90 %) as a colourless solid.
1 H NMR (CDCI3): 0.99 - 1.14 (4H, m), 1.23 - 1.29 (1 H, m), 1.41 - 1.46 (2H, m), 1.46
(9H, s), 1.73 - 1.79 (2H, m), 2.00 - 2.06 (2H, m), 2.50 (2H, t, J = 7.6 Hz), 2.62 - 2.65 (4H, m), 2.99 - 3.02 (4H, m), 3.05 (3H, s), 3.38 (1 H, br s), 4.38 (1 H, br s), 7.27 - 7.30 (1 H, d), 7.67 - 7.74 (2H, m).
Mass spectrum: AP+ Found: 351 ([M-BOC]H+). C24H38N2SO4 requires 450.
Description 28 frans-3-(2-(1-(4-Amino)cyclohexyl)ethyl)-7-methylsulphonyl-2,3,4,5-tetrahydro- 1 H- 3-benzazepine
A solution of trans-3-(2-(1-(4-Λ/-tert-butyloxycarbonyl)amino)cyclohexyl)ethyl-7- methylsulphonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine (1.3 g, 2.89 mmol) in dichloromethane (24 ml) and trifluoroacetic acid (6 ml) were stirred at room temperature for 2 h. The reaction mixture was then concentrated in vacuo and the residue partitioned between water (60 ml) and ethyl acetate (20 ml). The aqueous layer was separated, extracted with ethyl acetate (30 ml) and then basified to pH = 14 with 40 % sodium hydroxide. The oily suspension was then extracted with ethyl acetate (3 x 60 ml) and the combined organic layers dried (Na2Sθ4). The solvent was evaporated in vacuo to give the title compound (1.01 g, 100 %) as an off-white solid.
1 H NMR (CDCI3) δ: 0.90 - 1.12 (4H, m), 1.15 - 1.22 (1 H, m), 1.35 - 1.40 (2H, m),
1.72 - 1.78 (2H, m), 1.82 - 1.90 (2H, m), 2.45 - 2.52 (2H, m), 2.55 - 2.62 (5H, m), 2.98 - 3.02 (4H, m), 3.04 (3H, s), 7.27 (1 H, d, J = 7.8 Hz), 7.56 (1 H, s), 7.68 (1 H, d).
Mass spectrum: AP+ 351 (MH+): CιgH3oN2SO2 requires 350.
Description 29
3-(tert-Butyloxycarbonyl)-7-(5-(3-methyl)isoxazolyl)-2,3,4,5-tetrahydro-1H-3- benzazepine
A mixture of 7-acetyl-3-(terf-butyloxycarbonyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine (6.18 g, 21.4 mmol) and dimethylacetamide dimethylacetal (8 ml) was stirred at 125 °C. Methanol by-product was removed by means of a Dean-Stark apparatus. After 8 h, excess dimethyl acetamide dimethyl acetal was evaporated in vacuo to give a thick oily residue. Absolute ethanol (20 ml) and hydroxylamine hydrochloride (2.53
g, 36.4 mmol) were added and the resulting mixture was heated under reflux for 2 h. The ethanol was removed in vacuo and the crude product residue was purified by silica gel chromatography eluting with 10 - 100 % ethyl acetate in hexane to give the title compound as a colourless oil (6.1 g, 87 %).
Mass spectrum (API+): Found 351 (MNa+). C-| H24N2O3 requires 328.
1 H NMR (CDCI3) δ: 1.49 (9H, s), 2.35 (3H, s), 2.90 - 3.00 (4H, m), 3.50 - 3.65 (4H, m), 6.31 (1 H, s), 7.21 (1 H, d, J = 8 Hz), 7.50 - 7.53 (2H, m).
Description 30 7-(5-(3-Methyl)isoxazolyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine
A solution of 3-(tert-butyloxycarbonyl)-7-(5-(3-methyl)isoxazolyl)-2,3,4,5-tetrahydro- 1 H-3-benzazepine (5.1 g, 15.6 mmol) in CH CI2 (30 ml) and trifluoroacetic acid (10 ml) was heated under reflux for 2 h. Solvent was evaporated in vacuo and the residue partitioned between diethyl ether (150 ml) and water (150 ml). The aqueous phase was saturated with potassium carbonate then extracted with CH2CI (2 x 200 ml). The combined organic extracts were dried and evaporated in vacuo to give the title compound (3.15 g, 88 %).
Mass spectrum (API+): Found 229 (MH+). C-|4H-| 6N O requires 228.
1 H NMR (CDCI3) δ: 1.80 (1 H, br s), 2.34 (3H, s), 2.90 - 3.10 (8H, m), 6.30 (1 H, s), 7.17 (1 H, d, J = 8 Hz), 7.40 - 7.55 (2H, m).
Description 31 frans-3-(2-(1-(4-W--fert-Butyloxycarbonyl)amino)cyclohexyl)ethyl-7-(5-(3- methyl)isoxazolyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
Prepared from 7-(5-(3-methyl)isoxazolyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine in a manner similar to Description 2, in 92% yield.
Mass spectrum (API+): Found 454 (MH+). C2yH3gN3θ3 requires 453.
1 H NMR (CDCI3) δ: 1.00 - 1.10 (4H, m), 1.15 - 1.25 (1 H, m), 1.44 (9H, s), 1.55 -
1.70 (2H, m), 1.70 - 1.85 (2H, m), 1.95 - 2.05 (2H, m), 2.34 (3H, s), 2.45 - 2.55 (2H, m), 2.55 - 2.70 (4H, m), 2.90 - 3.00 (4H, m), 3.35 (1 H, m), 4.30 - 4.40 (1 H, m), 6.30 (1 H, s), 7.16 (1 H, d, J = 8 Hz), 7.45 - 7.55 (2H, m).
Description 32
fraπs-3-(2-(1-(4-Amino)cyclohexyl)ethyl-7-(5-(3-methyl)isoxazolyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine
Prepared from fraπs-3-(2-(1 -(4-Λ/-tert-butyloxycarbonyl)amino)cyclohexyl)ethyl-7-(5- (3-methyl)isoxazolyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine in a manner similar to Description 3 in 99 % yield.
1 H NMR (CDCI3) δ: 0.90 - 1.10 (4H, m), 1.15 - 1.25 (1 H, m), 1.35 - 1.50 (4H, m),
1.70 - 1.80 (2H, m), 1.80 - 1.90 (2H, m), 2.34 (3H, s), 2.42 - 2.52 (2H, m), 2.55 - 2.72 (5H, m), 2.90 - 3.00 (4H, m), 6.30 (1 H, s), 7.16 (1 H, d, J = 8 Hz), 7.45 - 7.55 (2H, m).
Description 33
3-(fert-Butyloxycarbonyl)-7-methanesulphonyloxy-2,3,4,5-tetrahydro-1-tø-3- benzazepine
A solution of 3-(tert-butyloxycarbonyl)-7-hydroxy-2,3,4,5-tetrahydro-1 H-3- benzazepine (3.0 g, 0.011 mol), methanesulphonylchloride (1.44 g, 0.013 mol), triethylamine (1.27 g, 0.013 mol) and dichloromethane (50 ml) was stirred at room temperature for 18 h. The reaction mixture was then partitioned between dichloromethane (50 ml) and a saturated solution of sodium hydrogen carbonate (50 ml). The organic layer was separated, washed with water (50 ml) and then dried (Na SO4). The solvent was then evaporated in vacuo to give the title compound (3.85 g, 99 %) as a pale yellow oil.
1 H NMR (CDCI3) δ : 1.48 (9H, s), 2.86 - 2.92 (4H, m), 3.13 (3H, s), 3.53 - 3.56 (4H, m), 7.00 - 7.03 (2H, m), 7.13 - 7.16 (1 H, m).
Mass spectrum (AP+) : Found 242 [M-BOC]H+. C-|gH23NSO5 requires 341.
Description 34 7-Methanesulphonyloxy-2,3,4,5-tetrahydro-1H-3-benzazepine
A solution of 3-(tert-butyloxycarbonyl)-7-methanesulphonyloxy-2,3,4,5-tetrahydro- 1 H-3-benzazepine (3.8 g, 0.011 mol), trifluoroacetic acid (3.76 g, 0.033 mol) and dichloromethane (50 ml) was heated at 50 °C for 5h. The solvents were then evaporated in vacuo and the residue partitioned between water (200 ml) and ethyl acetate (150 ml). The aqueous layer was removed and washed with ethyl acetate (100 ml) and then basified to pH 14 with 40% sodium hydroxide. The suspension was then extracted with ethyl acetate (3 x 150 ml) and the combined organic layers
dried (Na SO4). The solvents were evaporated in vacuo to give the title compound
(2.15 g, 80 %) as a colourless oil.
1 H NMR (CDCI3) δ : 2.88 - 3.00 (8H, m), 3.13 (3H, s), 6.99 - 7.03 (2H, m), 7.12
(1 H, d).
Mass spectrum (AP+) : Found 242 (MH)+. C11 H15NSO3 requires 241.
Description 35 frans-3-(2-(1-(4-N-teι -Butyloxycarbonyl)amino)cyclohexyl)ethyl-7- methanesulphonyloxy-2,3,4,5-tetrahydro-1H-3-benzazepine
A mixture of 7-(methanesulphonyloxy)-2,3,4,5-tetrahydro-1 H-3-benzazepine (2.0 g, 8.3 mmol) and trat?s-2-(1-(4-N-tert-butyloxycarbonyl)amino)cyclohexyl acetaldehyde (1.37 g, 5.7 mmol) in dichloroethane (30 ml) was stirred at room temperature for 5 min, before sodium triacetoxyborohydride (1.69 g, 7.98 mmol) was addded in a single portion. After stirring at room temperature for 48 h, a saturated solution of sodium hydrogen carbonate (50 ml) was added and the two layers separated. The aqueous layer was extracted with dichloromethane (3 x 60 ml) and the combined organic layers were dried (Na2Sθ4). The solvent was then evaporated in vacuo and the residue purified by column chromatography (silica gel, ethyl acetate) to give the title compound (2.54 g, 95 %) as a white solid.
1 H NMR (CDCI3) δ : 0.9 - 1.25 (7H, m), 1.44 (9H, s), 1.70 - 1.80 (2H, m), 1.90 -
2.05 (2H, m), 2.42 - 2.50 (2H, m), 2.55 - 2.65 (4H, m), 2.88 - 2.95 (4H, m), 3.12 (3H, s), 3.36 (1 H, br s), 4.34 (1 H, br s), 6.98 - 7.02 (2H, m), 7.08 - 7.12 (1 H, d).
Mass spectrum (AP+) : Found 467 [MH+]. C24H3sN2Sθ5 requires 466.
Description 36 frans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-methanesulphonyloxy-2,3,4,5- tetrahydro-1 H- 3-benzazepine
A solution of trans-3-(2-(1-(4-N-ferf-butyloxycarbonyl)amino)cyclohexyl)ethyl-7- methanesulphonyloxy-2,3,4,5-tetrahydro-1 H-3-benzazepine, trifluoroacetic acid (8 ml) and dichloromethane (32 ml), were stirred at room temperature for 2 h, under argon. The solvents were then evaporated in vacuo and the residue partitioned between water (150 ml) and ethyl acetate (60 ml). The aqueous layer was removed and washed with ethyl acetate (50 ml). The aqueous layer was then basified to pH
14 with 40% sodium hydroxide. The suspension was then extracted with ethyl acetate (3 x 80 ml) and the combined organic layers dried (Na2Sθ4). The solvents were evaporated in vacuo to give the title compound (1.78 g, 93 %) as an oil which crystallised on standing. 1 H NMR (CDCI3) δ : 0.95 - 1.45 (7H, m), 1.70 - 1.80 (2H, m), 1.80 - 1.90 (2H, m), 2.49 (2H, t, J = 7.8 Hz), 2.55 - 2.65 (5 H, m), 2.88 - 2.95 (4H, m), 3.12 (3H, s), 6.99 - 7.02 (2H, m), 7.11 (1 H, d, J = 8 Hz). Mass Spectrum (AP+): Found 367 (MH+). C-|gH3oN2SO3 requires 366. Examples The Compounds of Examples tabulated below (Tables 1 - 3) were all prepared using the following general method:-
A mixture of the appropriate fraπs-2-(2-(1 -(4-amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine (0.35 mmol), the appropriate acid (0.35 mmol), 1- ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.35 mmol), 1- hydroxybenzotriazole (catalytic amount) and dichloromethane (5ml) was shaken for 16h. Saturated sodium bicarbonate (4ml) was then added and the mixture shaken for 0.25h. Chromatography of the organic layer on silica with 50 - 100% ethyl acetate in hexane and 0 - 10% methanol in ethyl acetate gradient elution gave the title compounds.
Table 1.
Table 2.
Table 3.
Table 4.
The substituted benzazepines required as intermediates for the compounds of Table 5 were prepared from the compounds of Descriptions 8, 9, or 13, using standard methods for functional group transformation and heterocyclic ring synthesis or by palladium-catalysed cross-coupling reactions.
Table 5
Example 12 frans-(£)-7-Cyano-3-(2-(1 -(4-(3-(4- fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1H-3- benzazepine
A mixture of trans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-cyano-2,3,4,5-tetrahdyro- 1 H-3-benzazepine (103 mg, 0.35 mmol), 4-fluorocinnamic acid (58 mg, 0.35 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (67 mg, 0.35 mmol), and 1 -hydroxybenzotriazole (20 mg, 0.15 mmol) in dichloromethane (8 ml) was shaken at room temperature for 16 h. The reaction mixture was washed with saturated sodium bicarbonate (4 ml). The resulting precipitate was collected by filtration, washed with water (2 x 10 ml), and dried to give the title compound (87 mg, 56%) as a colourless solid.
Mass spectrum (API+): Found 446 (MH+). C2sH32FN3θ requires 445.
1 H NMR (DMSO-d6) δ: 0.94 - 1.31 (8H, m), 1.81 (4H, m), 2.40 (5H, m), 3.04 (4H, m), 3.63 (1 H, m), 6.54 (1 H, d, J = 16 Hz), 7.32 (4H, m), 7.59 (4H, m), 7.99 (1 H, d, J = 8 Hz).
Example 13 frans-7-Cyano-3-(2-(1-(4-(3-pyrrolo[2,3- b]pyridyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine
A mixture of trans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-cyano-2,3,4,5-tetrahydro- 1 H-3-benzazepine (103 mg, 0.35 mmol), 3-pyrrolo[2,3-b]pyridyl carboxylic acid (56 mg, 0.35 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (67
mg, 0.35 mmol) and 1 -hydroxybenzotriazole (20 mg, 0.15 mmol) in dichloromethane (8 ml) was shaken at room temperature for 16 h. The reaction mixture was washed with saturated aqueous sodium bicarbonate (4 ml). The resulting precipitate was collected by filtration, washed with water (2 x 10 ml) and dried to give the title compound (81 mg, 0.18 mmol, 53%) as a colourless solid.
Mass spectrum (API+): Found 442 (MH+). C 7H31 N5O requires 441.
1 H NMR (DMSO-d6) δ: 1.02 (2H, m), 1.15 - 1.45 (6H, m), 1.81 (4H, m), 2.50 (5H, m), 2.91 (4H, m), 3.73 (1 H, m), 7.14 (1 H, m), 7.32 (1 H, d, J = 8 Hz), 7.57 (2H, m), 7.73 (1 H, d, J = 8 Hz), 8.16 (1 H, m), 8.25 (1 H, m), 8.42 (1 H, m), 12.03 (1 H, br s).
Example 14 fraπs-7-Cyano-3-(2-(1-(4-(3-(3-(5-methyl)-1,2,4-oxadiazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1- f-3-benzazepine
A mixture of trans -3-(2-(1-(4-amino)cyclohexyl)ethyl-7-cyano-2,3,4,5-tetrahydro- 1 H-3-benzazepine (103 mg, 0.35 mmol), 3-(3-(5-methyl)-1 ,2,4-oxodiazolyl)benzoic acid (71 mg, 0.35 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (67 mg, 0.35 mmol) and 1 -hydroxybenzotriazole (20 mg, 0.15 mmol) in dichloromethane (8 ml) was shaken at room temperature for 16 h. The reaction mixture was washed with saturated aqueous sodium bicarbonate (4 ml). The organic layer was pipetted onto a 10 g pre-packed silica column and eluted with 30 - 100% ethyl acetate in hexane. The fractions containing the title compound were combined and evaporated in vacuo to give the title compound (119 mg, 71%) as a colourless solid.
Mass spectrum (API+): Found 484. C2 H33N5θ2 requires 483.
1 H NMR (CDCI3) δ: 1.08 - 1.35 (5H, m), 1.45 (2H, m), 1.84 (2H, m), 2.12 (2H, m),
2.50 (2H, m), 2.62 (4H, m), 2.68 (3H, s), 2.96 (4H, m), 3.95 (1 H, m), 6.02 (1 H, d, J = 8 Hz), 7.17 (1 H, d, J = 8 Hz), 7.41 (2H, m), 7.57 (1 H, t, J = 8 Hz), 7.98 (1 H, m), 8.17 (1 H, m), 8.32 (1 H, m).
Example 15 frans-(£)-7-Cyano-3-(2-(1-(4-(5-quinolinyl)carboxamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1H-benzazepine
A mixture of trans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-cyano-2,3,4,5-tetrahydro- 1 H-benzazepine (0.10 g, 0.34 mmol), quinoline-5-carboxylic acid (0.057 g, 0.37
mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.065 g, 0.34 mmol), 1 -hydroxybenzotriazole (catalytic amount) and dichloromethane (8 ml) was shaken for 16 h. Saturated sodium bicarbonate (4 ml) was then added and the mixture shaken for 0.25 h. Chromatography on the organic layer on silica eluting with a gradient of 30 - 100% ethyl acetate in hexane and then 0 - 10% methanol in ethyl acetate gave the title compound (0.130 g, 86%).
Mass spectrum (API+) Found 453 (MH+). C2 H32N4θ requires 452.
1 H NMR (CDCI3) δ: 1.12 - 1.35 (5H, m), 1.41 - 1.51 (2H, m), 1.83 - 1.89 (2H, m),
2.15 - 2.24 (2H, m), 2.48 - 2.55 (2H, m), 2.60 - 2.66 (4H, m), 2.91 - 2.99 (4H, m), 3.97 - 4.13 (1 H, m), 5.86 (1 H, d, J = 8 Hz), 7.18 (1 H, d, J = 8 Hz), 7.37 - 7.49 (3H, m), 7.63 - 7.70 (2H, m), 8.15 - 8.20 (1 H, m), 8.71 - 8.76 (1 H, m), 8.94 - 8.96 (1 H, m).
Example 16 fra/?s-(£)-7-Cyano-3-(2-(1-(4-(3-(3- acetylamino)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-
3-benzazepine
A mixture of trans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-cyano-2,3,4,5-tetrahydro- 1 H-3-benzazepine (0.10 g, 0.34 mmol), 3-acetamido cinnamic acid (0.076 g, 0.42 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.071 g, 0.42 mmol), 1 -hydroxybenzotriazole (catalytic amount) and dichloromethane (8 ml) was shaken for 16 h. Saturated sodium bicarbonate (4 ml) was then added and the mixture shaken for 0.25 h. The precipitated solid was filtered off and washed with water then diethyl ether, and dried to give the title compound (0.12 g, 74%) as a colourless solid.
Mass spectrum (API+): Found 485 (MH+). C3QH36N4O requires 484.
1 H NMR (CDCI3 + CD3OD) δ: 1.02 - 1.35 (5H, m), 1.35 - 1.50 (2H, m), 1.77 - 1.82
(2H, m), 2.00 - 2.04 (2H, m), 2.17 (3H, s), 2.47 - 2.55 (6H, m), 2.93 - 2.99 (4H, m), 3.70 - 3.85 (1 H, m), 6.41 (1 H, d, J = 15 Hz), 7.17 - 7.30 (4H, m), 7.38 - 7.43 (3H, m), 7.50 (1 H, d, J = 16 Hz), 7.80 (1 H, s).
Example 17 frans-7-Cyano-3-(2-(1-(4-(6-(3,4-dihydro-3-oxo)-2H- benzoxazinyl)carboxamido)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H- benzazepine
A mixture of traπs-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-cyano-2,3,4,5-tetrahydro- 1 H-3-benzazepine (0.10 g, 0.34 mmol), 2,3-dihydro-3-oxo-4 --benzoxazine-6- carboxylic acid (0.072 g, 0.42 mmol), 1 -ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (0.071 g, 0.42 mmol), 1- hydroxybenzotriazole (catalytic amount) and dichloromethane (8 ml) was shaken for 16 h. Saturated sodium bicarbonate (4 ml) was then added and the mixture shaken for 0.25 h. The precipitated solid was filtered off and washed with water then diethyl ether, and dried to give the title compound (0.16 g, 100%) as a colourless solid.
Mass spectrum (API+): Found 473 (MH+). C28H32N4θ3 requires 472.
1 H NMR (DMSO-d6) δ: 0.95 - 1.50 (7H, m), 1.75 - 1.95 (4H, m), 2.40 - 2.65 (6H, m), 2.93 - 3.05 (4H, m), 3.69 - 3.82 (1 H, m), 4.67 (2H, s), 7.02 (1 H, d, J = 8 Hz), 7.39 (1 H, d, J = 8 Hz), 7.46 - 7.50 (2H, m), 7.65 (2H, m), 8.13 (1 H, d, J = 8 Hz).
Example 18 frans*(E)-7-Cyano-3-(2-(1 -(4-(3-(6-(1 ,2-dihydro-2- oxo)quinolinyl)propenoyl)amino)-cyclohexyl) ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine
A mixture of trans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-cyano-2,3,4,5-tetrahydro- 1 H-3-benzazepine (288 mg, 0.97 mmol), trans-3-(6-(1 ,2-dihydro-2-oxo)quinolinyl)- propenoic acid (250 mg, 1.16 mmol), 1 -ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (204 mg, 1.07 mmol), 1- hydroxybenzotriazole (catalytic amount) and DMF (20 ml) was shaken for 18 h. Saturated sodium bicarbonate (8 ml) was then added and the mixture shaken for 0.25 h. The resulting precipitate was filtered and dried in vacuo to give the title compound (370 mg, 77%) as a colourless solid.
Found: 495 (MH+). C3-| H34N4O2 requires 494.
1 H NMR (DMSO-d6) δ: 0.94 - 1.05 (2H, m), 1.10 - 1.30 (3H, m), 1.30 - 1.40 (2H, m), 1.74 - 1.80 (2H, m), 1.80 - 1.88 (2H, m), 2.44 (2H, t, J = 7.5 Hz), 2.45 - 2.55 (4H, m), 2.85 - 2.95 (4H, m), 3.55 - 3.65 (1 H, m), 6.50 - 6.60 (2H, m), 7.28 - 7.35 (2H, m), 7.40 (1 H, d, J = 16 Hz), 7.55 - 7.60 (2H, m), 7.68 - 7.72 (1 H, m), 7.81 (1 H, s), 7.93 (1 H, d, J = 16 Hz), 7.94 - 8.00 (2H, m).
Example 19
frans-(E)-7-Cyano-3-(2-(1-(4-(3-(2-fluoro-4- acetylamino)phenylpropenoyl)amino)-cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1H-
3-benzazepine
A mixture of frans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-cyano-2,3,4,5-tetrahydro- 1 H-3-benzazepine (150 mg, 0.51 mmol), (£)-(2-fluoro-4- acety!amino)phenylpropenoic acid (113 mg, 0.51 mmol), EDC. hydrochloride (97 mg, 0.51 mmol) and 1 -hydroxybenzotriazole in dichloromethane (10 ml) was shaken at room temperature for 16 h. The reaction mixture was washed with saturated aqueous sodium bicarbonate (4 ml) and the precipitate collected by filtration and then re-suspended in water and filtered before drying in vacuo to give the title compound as an off white solid (200 mg, 79%).
Mass spectrum (API+): Found 503. C3QH35FN4O2 requires 502.
1 H NMR δ (DMSO-d6 + TFA): 0.95 - 1.34 (5H, m), 1.61 (2H, m), 1.82 (4H, m), 2.07
(3H, s), 3.06 (2H, m), 3.18 (6H, m), 3.68 (3H, m), 6.59 (1 H, d, J = 16 Hz), 7.34 (2H, m), 7.39 - 7.63 (3H, m), 7.72 (2H, m), 8.03 (1 H, d, J = 8 Hz), 9.74 (1 H, br s), 10.29 (1 H, s).
Example 20 fra/ιs*(E)-7-Cyano-3-(2-(1 -(4-(3-(8-(1 ,2-dihydro-2- oxo)quinolinyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine
A mixture of frans-3-(2-(1-(4-amino)cyclohexyl)ethyl-7-cyano-2,3,4,5-tetrahydro-1 H- 3-benzazepine (0.25 g, 0.84 mmol), (£)-3-(8-(1 ,2-dihydro-2- oxo)quinolinyl)propenoic acid (0.27 g, 1.2 mmol), EDC. hydrochloride (0.3 g, 1.5 mmol) and 1 -hydroxybenzotriazole (50 mg) in DMF (10 ml) was allowed to stir at 80 °C for 4 h, then poured into water (500 ml). The precipitate was collected by filtration and then re-suspended in aqueous sodium bicarbonate solution. Resulting solid was collected by filtration, then washed with water and diethyl ether, then was dried in vacuo to give the title compound (0.42 g, 95 %) as a yellow solid.
Found: 495 (MH+). C31 H34N4O2 requires 494. δ (DMSO-d6 + TFA): 1.00 - 1.15 (2H, m), 1.15 - 1.30 (3H, m), 1.50 - 1.70 (2H, m),
1.70 - 1.85 (2H, m), 1.85 - 1.95 (2H, m), 2.95 - 3.30 (8H, m), 3.60 - 3.80 (3H, m),
6.45 - 6.60 (2H, m), 7.23 (1 H, t, J = 8 Hz), 7.46 (1 H, d, J = 8 Hz), 7.60 - 7.80 (4H, m), 7.94 (1 H, d, J = 10 Hz), 7.95 - 8.10 (3H, m), 9.70 (1 H, br s).
Example 21 frans-7-Cyano-3-(2-(1 -(4-(5-(8- fluoro)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine
A mixture of frans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-cyano-2,3,4,5-tetrahydro- 1 H-3-benzazepine (0.162 g, 0.545 mmol), 8-fluoroquinoline-5-carboxylic acid (0.115 g, 0.6 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.115 g, 0.6 mmol) and 1 -hydroxybenzotriazole hydrate (0.01 g, 0.065 mmol) in dichloromethane (7 ml) was shaken for 18 h. Saturated aqueous sodium hydrogen carbonate (6 ml) was added and shaking continued for 0.5 h. The organic layer was separated and pipetted onto a column of silica (10 g). Elution with 30 - 100% ethyl acetate - hexane gradient then 1 - 10% methanol - ethyl acetate gradient yielded the title compound as a colourless solid (0.22 g, 85%).
Mass spectrum (API+): Found 471 (MH+). C2 H3i FN4O requires 470.
1 H NMR (CDCI3) δ: 1.05 - 1.40 (5H, m), 1.45 (2H, m), 1.85 (2H, m), 2.20 (2H, m),
2.55 (2H, m), 2.63 (4H, m), 2.96 (4H, m), 4.00 (1 H, m), 5.86 (1 H, d, J = 8 Hz), 7.17 (1 H, d, J = 8 Hz), 7.30 - 7.45 (3H, m), 7.54 (1 H, m), 7.62 (1 H, m), 8.80 (1 H, d, J = 8 Hz), 9.01 (1 H, m).
Example 24 fraπs-3-(2-(1-(4-(5-(2-Methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1W-3-benzazepine
A mixture of frans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-methylsulphonyl-2,3,4,5- tetrahydro-1 H-3-benzazepine (100 mg, 0.29 mmol), 2-methyl-quinoline-5-carboxylic acid (64 mg, 0.34 mmol), 1-ethyl-3-(3-dimethyIaminopropyl)carbodiimide hydrochloride (59 mg, 0.31 mmol) and 1 -hydroxybenzotriazole (cat. amt.) in dichloromethane (10 ml) was shaken at room temperature for 18 h. A saturated
solution of sodium bicarbonate (4 ml) was then added and the mixture shaken for 0.25 h. The organic layer was then applied directly to a silica column eluted with a gradient of 30 - 100% ethyl acetate in hexane and then 0 - 10% methanol in ethyl acetate to give the title compound (95 mg, 66 %) as a colourless solid.
1 H NMR δ (CDCI3) 1.15 - 1.30 (5H, m), 1.44 - 1.50 (2H, m), 1.82 - 1.88 (2H, m),
2.15 - 2.20 (2H, m), 2.53 (2H, t, J = 7.6 Hz), 2.62 - 2.68 (4H, m), 2.75 (3H, s), 2.98 - 3.02 (4H, m), 3.04 (3H, s), 3.95 - 4.05 (1 H, m), 5.84 (1 H, d, J = 8.2 Hz), 7.28 (1 H, d, J = 7.9 Hz), 7.35 (1 H, d, J = 8.8 Hz), 7.56 - 7.70 (4H, m), 8.08 (1 H, d), 8.62 (1 H, d).
Mass spectrum: API+ 520 (MH+): C30H37N3SO3 requires 519.
Example 25 fraπs-3-(2-(1 -(4-(3-(3-(5-Methyl)-1 ,2,4- oxadiazolyl)benzoyl)amino)cyclohexyl)ethyl)-7-methylsulphonyl-2,3,4,5- tetrahydro-1 H-3-benzazepine
A mixture of trans-3-(2-(1 -(4-amino)cyclohexyl)-7-methylsulphonyl-2,3,4,5- tetrahydro-1 H-3-benzazepine (100 mg, 0.29 mmol), 3-(3-(5-methyl)-1 ,2,4- oxadiazolyl)-benzoic acid (69 mg, 0.34 mmol), 1 -ethyl-3-(3- dimethylaminopropyl)carbodiimide hydrochloride (59 mg, 0.31 mmol) and 1 - hydroxybenzotriazole (cat. amt.) in dichloromethane (10 ml) was shaken at room temperature for 18 h. A saturated solution of sodium bicarbonate (4 ml) was then added and the mixture shaken for 0.25 h. The organic layer was then applied directly to a silica column eluted with a gradient of 30 - 100% ethyl acetate in hexane and then 0 - 10% methanol in ethyl acetate to give the title compound (103 mg, 69 %) as a colourless solid.
1 H NMR δ (CDCI3): 1.08 - 1.30 (5H, m), 1.40 - 1.46 (2H, m), 1.80 - 1.85 (2H, m),
2.08 - 2.15 (2H, m), 2.52 (2H, t, J = 7.8), 2.60 - 2.65 (4H, m), 2.68 (3H, s), 2.98 - 3.02 (4H, m), 3.05 (3H, s), 3.90 - 4.00 (1 H, m), 6.01 (1 H, d, J = 8.0 Hz), 7.28 (1 H, d, J = 7.28 Hz), 7.57 (1 H, t, J = 7.8 Hz), 7.65 - 7.70 (2H, m), 8.0 (1 H, d), 8.19 (1 H, d, J = 7.7 Hz), 8.32 (1 H, s).
Mass spectrum: API+ 537 (MH+): C2gH36N4SO4 requires 536.
Example 26 frans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine, hydrochloride
A mixture of trans-3-(2-(1-(4-amino)cyclohexyl)-7-(5-(3-methyl)-1 ,2,4-oxadiazolyl)- 2,3,4,5-tetrahydro-1 H-3-benzazepine (21.0 g, 59.3 mmol), pyrrolo[2,3-b]pyridyl-3- carboxylic acid (10.57 g, 65.2 mmol), EDC hydrochloride (12.46 g, 64.4 mmol) and HOBT (0.5 g) in CH2CI2 (630 ml) and DMF (84 ml) was stirred at ambient temperature for 16 h. Saturated aqueous sodium bicarbonate (350 ml) was added and the mixture stirred for 0.25 h. The precipitate was collected by filtration, washed in turn with water and diethyl ether and dried in vacuo to give the free base of the title compound (18.0 g, 61 %).
Mass spectrum (API+): Found 499 (MH+). C29H34N6O2 requires 498.
NMR (DMSO-d6) δ: 0.90 - 1.10 (2H, m), 1.10 - 1.40 (5H, m), 1.70 - 1.90 (4H, m),
2.40 - 2.70 (6H, m), 2.96 (3H, s), 3.31 (4H, m), 3.89 (1 H, m), 7.15 (1 H, m), 7.36
(1 H, d, J = 8 Hz), 7.71 (1 H, d, J = 8 Hz), 7.75 - 7.85 (2H, m), 8.12 (1 H, s), 8.20 (1 H, s), 8.35 (1 H, d, J = 8 Hz), 12.02 (1 H, br s).
To a suspension of the above free base (18.0 g, 36 mmol) in 10% methanol- dichloromethane (500 ml) was added a 1 M solution of HCI in diethyl ether (37.08 ml). The resulting solution was evaporated in vacuo and the residue crystallised from methanol to give the title compound as a colourless solid (12.5 g, m.p. 275 - 276 °C).
Example 27 frans-(E)-7-(3-(5-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1W-3-benzazepine
Alternative Name: (2£)-3-(4-fluorophenyl)-Λ/-[trans-4-[2-[2,3,4,5-tetrahydro-7-(5- methyl-1 ,2,4-oxadiazol-3-yl)-1 H-3-benzazepin-3-yl]ethyl]cyclohexyl]-2-propenamide
A mixture of trat7s-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-(3-(5-methyl)-1 ,2,4- oxadiazolyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine (0.1 g, 0.28 mmol), (£)-4- fluorocinnamic acid (0.046 g, 0.28 mmol), EDC hydrochloride (0.06 g, 0.31 mmol) and HOBT (0.015 g) in dichloromethane (8 ml) was stirred at ambient temperature
for 64 h, then was washed with saturated aqueous sodium bicarbonate (4 ml). The organic phase was purified by silica gel chromatography eluting with 0 - 10 % methanol in ethyl acetate, to give the title compound (0.12 g, 85 %) as a colourless solid.
Mass spectrum (API+): Found 503 (MH+). C3oH35FN4O2 requires 502.
NMR (CDCI3) δ: 1.10 - 1.80 (4H, m), 1.25 (1 H, m), 1.44 (2H, m), 1.78 (2H, m), 2.06
(2H, m), 2.50 (2H, m), 2.60 - 2.70 (7H, m), 2.90 - 3.00 (4H, m), 3.85 (1 H, m), 5.39
(1 H, d, J = 8 Hz), 6.26 (1 H, d, J = 16 Hz), 7.05 (2H, t, J = 8 Hz), 7.20 (1 H, d, J = 8
Hz), 7.47 (2H, m), 7.57 (1 H, d, J = 16 Hz), 7.80 - 7.90 (2H, m).
A mixture of traπs-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-(3-(5-methyl)-1 ,2,4- oxadiazolyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine (16.0g, 0.045 mol), (E)-4- fluorocinnamic acid (7.5g, 0.045 mol), EDC hydrochloride (9.53 g, 0.050 mol), and HOBT (0.78g, 0.006 mol) in dichloromethane (0.78L) was stirred under argon at ambient temperature for 111 h. Saturated aqueous sodium bicarbonate (1 L) was added and after stirring for 0.25h, the mixture was filtered and the solid washed with saturated aqueous sodium bicarbonate (2 x 0.25L), water (3 x 0.25L), diethyl ether (3 x 0.25L) and dried in vacuo to afford the title compound (18.4g, 81%) as a colourless solid.
The filtrate was separated and the aqueous layer extracted with dichloromethane (2 x 0.3L). The combined extracts were dried and evaporated in vacuo to afford a pale yellow solid (4.5g). Sequential trituration with dichloromethane (0.08L), saturated aqueous sodium bicarbonate (1 x 0.5L; 2 x 0.2L), water (3 x 0.2L), and diethyl ether (3 x 0.2L) followed by drying in vacuo afforded the title compound (2.8g, 12%) as a colourless solid.
Both batches had spectroscopic data identical to that described above. To a solution of the free base obtained above (21.2g, 0.042 mol) in dichloromethane (0.55L) and methanol (0.1 L) was added 1 M hydrogen chloride in diethyl ether (0.051 L, 0.05mol). The resulting solution was evaporated in vacuo and the residue crystallised from methanol to afford (2£)-3-(4-fluorophenyl)-Λ/- [fra/is-4-[2-[2,3,4,5-tetrahydro-7-(5-methyl-1 ,2,4-oxadiazol-3-yl)-1 H-3-benzazepin-3- yl]ethyl]cyclohexyl]-2-propenamide monohydrochloride (19.8g, 91%) as a colourless solid m.p. 259-261 °C. NMR (D6-DMSO) δ: 1.00 - 1.09 (2H, m), 1.15 - 1.28 (3H, m), 1.60 - 1.70 (2H, m),
1.70 - 1.80 (2H, m), 1.80 - 1.90 (2H, m), 2.66 (3H, s), 2.95 - 3.25 (6H, m), 3.35 -
3.50 (2H, m), 3.55 - 3.75 (3H, m), 6.55 (1 H, d, J = 16 Hz), 7.22 - 7.27 (2H, m), 7.39 (1 H, d, J = 16Hz), 7.40 - 7.45 (1 H, m), 7.55 - 7.64 (2H, m), 7.80 - 7.85 (1 H, m), 7.87 (1 H, s), 7.95 - 8.05 (1 H, m), 10.60 (1 H, br s).
Example 28 trans-(£)-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine
A mixture of frans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-(5-(3-methyl)-1 ,2,4- oxadiazolyl)-2,3,4,5-tetrahydro-1 --3-benzazepine (0.1 g, 0.28 mmol), (E)-4- fluorocinnamic acid (0.046 g, 0.28 mmol) EDC hydrochloride (0.06 g, 0.31 mmol) and HOBT (0.015 g) in dichloromethane (8 ml) was stirred at ambient temperature for 64 h, then was washed with saturated aqueous sodium bicarbonate (4 ml). The organic phase was purified by silica gel chromatography eluting with 0 - 10 % methanol in ethyl acetate to give the title compound (0.12 g, 85 %) as a colourless solid.
Mass spectrum (API+): Found 503 (MH+). C30H35FN4O2 requires 502. NMR (CDCI3) δ: 1.10 - 1.30 (5H, m), 1.40 - 1.47 (2H, m), 1.78 - 1.82 (2H, m), 2.00 - 2.10 (2H, m), 2.46 (3H, s), 2.47 - 2.52 (2H, m), 2.60 - 2.70 (4H, m), 2.95 - 3.05 (4H, m), 3.86 (1 H, m), 5.38 (1 H, d, J = 8 Hz), 6.26 (1 H, d, J = 16 Hz), 7.05 (2H, t, J = 8 Hz), 7.24 (1 H, d, J = 8 Hz), 7.47 (2H, dd, J = 5, 8 Hz), 7.57 (1 H, d, J = 16 Hz), 7.80 - 7.90 (2H, m).
Example 29 frans-(E)-7-(5-(3-Methyl)isoxazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine
A mixture of trans-3-(2-(1-(4-amino)cyclohexyl)ethyl-7-(5-(3-methyl)isoxazolyl)- 2,3,4,5-tetrahydro-1 H-3-benzazepine (0.1 g, 0.28 mmol), 4-fluorophenylacetic acid (0.044 g, 0.28 mmol), EDC hydrochloride (0.065 g, 0.31 mmol) and HOBT (0.02 g) in CH CI2 (8 ml) was stirred at ambient temperature for 16 h, then was washed with saturated sodium bicarbonate (4 ml). The organic phase was purified by silica gel chromatography eluting with 0 - 10 % methanol in ethyl acetate to give the title compound (0.1 g, 73 %).
Mass spectrum (API+): Found 490 (MH+). C3QH36FN3O2 requires 489.
1 H NMR δ (CDCI3): 0.90 - 1.10 (4H, m), 1.10 - 1.20 (1 H, m), 1.30 - 1.40 (2H, m),
1.70 - 1.80 (2H, m), 1.85 - 1.95 (2H, m), 2.34 (3H, s), 2.40 - 2.50 (2H, m), 2.55 - 2.70 (4H, m), 2.90 - 3.00 (4H, m), 3.50 (2H, s), 3.65 - 3.80 (1H, m), 5.12 (1H, d, J = 8 Hz), 6.30 (1 H, s), 7.03 (2H, t, J = 8 Hz), 7.15 (1 H, d, J = 8 Hz), 7.19 - 7.25 (2H, m), 7.45 - 7.52 (2H, m).
Example 148 frans-7-(5-(3-Methyl)-1,2,4-oxadiazolyl)-3-(2-(1-(4-(4-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine
A mixture of tt-ans-3-(2-(1-(4-amino)cyclohexyl)ethyl)-7-(5-(3-methyl)-1 ,2,4- oxadiazolyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine (0.1 g, 0.28 mmol), (4- fluoro)phenylacetic acid (0.044 g, 0.28 mmol), EDC hydrochloride (0.054 g, 0.28 mmol) and HOBT (0.015 g) in dichloromethane (5 ml) was shaken at ambient temperature for 16 h, and saturated aqueous sodium bicarbonate (4 ml) added. The organic phase was purified by silica gel chromatography eluting with 30-100% ethyl acetate in hexane, then 0 - 10 % methanol in ethyl acetate gradient elution to give the title compound (0.095 g, 70 %) as a colourless solid.
Mass spectrum (API+): Found 491 (MH+). C2gH3sFN4θ2 requires 490.
1 H NMR δ (CDCI3): 0.90 - 1.30 (5H, m), 1.35 - 1.50 (2H, m), 1.70 - 1.80 (2H, m),
1.85 - 1.95 (2H, m), 2.46 (3H, s), 2.40 -2.50 (2H, m), 2.55 - 2.65 (4H, m), 2.95 - 3.00 (4H, m), 3.50 (2H, s), 3.60 - 3.80 (1 H, m), 5.13 (1 H, d, J = 8Hz), 6.95 - 7.08 (2H, m), 7.15 - 7.30 (3H, m), 7.80 - 7.90 (2H, m).
Example 149 frans-3-(2-(1-(4-(5-(2-Methyl)quinolinyl)carboxamide)cyclohexyl)ethyl)-7- methanesulphonyloxy-2,3,4,5-tetrahydro-1H-3-benzazepine
A mixture of tra/7S-3-(2-(1-(4-amino)cyclohexyl)ethyI)-7-methanesulphonyloxy- 2,3,4,5-tetrahydro-1 --3-benzazepine (150 mg, 0.41 mmol), 2-methyl-quinoline-5- carboxylic acid (92 mg, 0.49 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (86 mg, 0.45 mmol) and 1 -hydroxybenzotriazole (cat. amt.) in
dichloromethane (10 ml) was shaken at room temperature for 18 h. A saturated solution of sodium bicarbonate (4 ml) was added and the mixture shaken for 0.25 h. The organic layer was then applied directly to a silica column eluted with a gradient of 30 - 100 % ethyl acetate in hexane and then 0 - 10% methanol in ethyl acetate to give the title compound (161 mg, 74%) as a colourless solid.
1 H NMR (CDCI3) δ : 1.15 - 1.30 (5H, m), 1.45 - 1.50 (2H, m), 1.82 - 1.90 (2H, m),
2.15 - 2.20 (2H, m), 2.50 - 2.55 (2H, m), 2.60 - 2.68 (4H, m), 2.75 (3H, s), 2.90 - 2.95 (4H, m), 3.13 (3H, s), 3.95 - 4.05 (1 H, m), 5.82 (1 H, d, J = 8.2 Hz), 7.00 - 7.03 (2H, m), 7.12 (1 H, d, J = 7.8 Hz), 7.35 (1H, d, J = 8.8 Hz), 7.55 - 7.70 (2H, m), 8.08 (1 H, d, J = 8.3 Hz), 8.61 (1 H, d).
Mass Spectrum (AP+) : Found 536 (MH+). C30H37N3SO4 requires 535.
BIOLOGICAL EXAMPLES
The inhibitory effects of compounds at the M3 mAChR of the present invention are determined by the following in vitro and in vivo functional assays:
Analysis of Inhibition of Receptor Activation by Calcium Mobilization: Stimulation of mAChRs expressed on CHO cells were analyzed by monitoring receptor-activated calcium mobilization as previously described (Sarau, H. M., R. S. Ames, J. Chambers, C. Ellis, N. Elshourbagy, J. J. Foley, D. B. Schmidt, R. M. Muccitelli, O. Jenkins, P. R. Murdock, N. C. Herrity, W. Halsey, G. Sathe, A. I. Muir, P. Nuthulaganti, G. M. Dytko, P. T. Buckley, S. Wilson, D. J. Bergsma, and D. W. Hay. 1999. Identification, molecular cloning, expression, and characterization of a cysteinyl leukotriene receptor. Mol Pharmacol 56:657-663). CHO cells stably expressing M3 mAChRs were plated in 96 well black wall/clear bottom plates. After 18 to 24 hours, media was aspirated and replaced with 100 μl of load media (EMEM with Earl's salts, 0.1% RIA-grade BSA (Sigma, St. Louis MO), and 4 μM Fluo-3-acetoxymethyl ester fluorescent indicator dye (Fluo-3 AM, Molecular Probes, Eugene, OR) and incubated 1 hr at 37° C. The dye-containing media was then aspirated, replaced with fresh media (without Fluo-3 AM), and cells were incubated for 10 minutes at 37° C. Cells were then washed 3 times and incubated for 10 minutes at 37° C in 100 μl of assay buffer (0.1% gelatin (Sigma), 120 mM NaCI, 4.6 mM KCI, 1 mM KH2 PO4, 25 mM NaH CO3, 1.0 mM CaCI2, 1.1 mM MgCI2, 11 mM glucose, 20mM HEPES (pH 7.4)). 50 μl of compound (1x10"1 1
- 1x10"5 M final in the assay) was added and the plates were incubated for 10 min. at 37° C. Plates were then placed into a fluorescent light intensity plate reader (FLIPR, Molecular Probes) where the dye loaded cells were exposed to excitation light (488 nm) from a 6 watt argon laser. Cells were activated by adding 50 μl of acetylcholine (0.1-10 nM final), prepared in buffer containing 0.1% BSA, at a rate of 50 μl/sec. Calcium mobilization, monitored as change in cytosolic calcium concentration, was measured as change in 566 nm emission intensity. The change in emission intensity is directly related to cytosolic calcium levels (Sullivan, E., E. M. Tucker, and I. L. Dale. 1999. Measurement of [Ca2+] using the Fluorometric Imaging Plate Reader (FLIPR). Methods Mol Biol 114:125-133). The emitted fluorescence from all 96 wells is measured simultaneously using a cooled CCD camera. Data points are collected every second. This data was then plotting and analyzed using GraphPad PRISM software.
Methacholine-induced bronchoconstriction Airway responsiveness to methacholine was determined in awake, unrestrained BalbC mice (n = 6 each group). Barometric plethysmography was used to measure enhanced pause (Penh), a unitless measure that has been shown to correlate with the changes in airway resistance that occur during bronchial challenge with methacholine (Hamelmann, E., J. SCHWARZE, K. TAKEDA, A. OSHIBA, G. a. LARSEN, C. a. IRVIN, and E. a. GELFAND. 1997. Noninvasive Measurement of Airway Responsiveness in Allergic Mice Using Barometric Plethysmography. Am.J.Respir.Crit.Care Med. 156:766-775). Mice were pretreated with 50 μl of compound (0.003-10 μg/mouse) in 50 μl of vehicle (10% DMSO) intranasally, i.v., i.p. or p.o, and were then placed in the plethysmography chamber. Once in the chamber, the mice were allowed to equilibrate for 10 min before taking a baseline Penh measurement for 5 minutes. Mice were then challenged with an aerosol of methacholine (10 mg/ml) for 2 minutes. Penh was recorded continuously for 7 min starting at the inception of the methacholine aerosol, and continuing for 5 minutes afterward. Data for each mouse were analyzed and plotted by using GraphPad PRISM software. The present compounds are useful for treating a variety of indications, including but not limited to respiratory-tract disorders such as chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis; gastrointestinal-tract disorders
such as irritable bowel syndrome, spasmodic colitis, gastroduodenal ulcers, gastrointestinal convulsions or hyperanakinesia, diverticulitis, pain accompanying spasms of gastrointestinal smooth musculature; urinary-tract disorders accompanying micturition disorders including neurogenic pollakisuria, neurogenic bladder, nocturnal enuresis, psychosomatic bladder, incontinence associated with bladder spasms or chronic cystitis, urinary urgency or pollakiuria, and motion sickness. Methods of administering the present compounds will be readily apparent to the skilled artisan.
Dry powder compositions for topical delivery to the lung by inhalation may, for example, be presented in capsules and cartridges of for example gelatine, or blisters of for example laminated aluminium foil, for use in an inhaler or insufflator. Formulations generally contain a powder mix for inhalation of the compound of the invention and a suitable powder base (carrier substance) such as lactose or starch. Use of lactose is preferred. Each capsule or cartridge may generally contain between 20μg-10mg of the compound of formula (I) optionally in combination with another therapeutically active ingredient. Alternatively, the compound of the invention may be presented without excipients. Suitably, the medicament dispenser is of a type selected from the group consisting of a reservoir dry powder inhaler (RDPI), a multi-dose dry powder inhaler (MDPI), and a metered dose inhaler (MDI). By reservoir dry powder inhaler (RDPI) it is meant an inhaler having a reservoir form pack suitable for comprising multiple (un-metered doses) of medicament in dry powder form and including means for metering medicament dose from the reservoir to a delivery position. The metering means may for example comprise a metering cup, which is movable from a first position where the cup may be filled with medicament from the reservoir to a second position where the metered medicament dose is made available to the patient for inhalation. By multi-dose dry powder inhaler (MDPI) is meant an inhaler suitable for dispensing medicament in dry powder form, wherein the medicament is comprised within a multi-dose pack containing (or otherwise carrying) multiple, define doses (or parts thereof) of medicament. In a preferred aspect, the carrier has a blister pack form, but it could also, for example, comprise a capsule-based pack form or a carrier onto which medicament has been applied by any suitable process including printing, painting and vacuum occlusion.
The formulation can be pre-metered (eg as in Diskus, see GB 2242134 or Diskhaler, see GB 2178965, 2129691 and 2169265) or metered in use (eg as in Turbuhaler, see EP 69715). An example of a unit-dose device is Rotahaler (see GB 2064336). The Diskus inhalation device comprises an elongate strip formed from a base sheet having a plurality of recesses spaced along its length and a lid sheet hermetically but peelably sealed thereto to define a plurality of containers, each container having therein an inhalable formulation containing a compound of formula (I) preferably combined with lactose. Preferably, the strip is sufficiently flexible to be wound into a roll. The lid sheet and base sheet will preferably have leading end portions which are not sealed to one another and at least one of the said leading end portions is constructed to be attached to a winding means. Also, preferably the hermetic seal between the base and lid sheets extends over their whole width. The lid sheet may preferably be peeled from the base sheet in a longitudinal direction from a first end of the said base sheet. In one aspect, the multi-dose pack is a blister pack comprising multiple blisters for containment of medicament in dry powder form. The blisters are typically arranged in regular fashion for ease of release of medicament therefrom. In one aspect, the multi-dose blister pack comprises plural blisters arranged in generally circular fashion on a disc-form blister pack. In another aspect, the multi- dose blister pack is elongate in form, for example comprising a strip or a tape. Preferably, the multi-dose blister pack is defined between two members peelably secured to one another. US Patents Nos. 5,860,419, 5,873,360 and 5,590,645 describe medicament packs of this general type. In this aspect, the device is usually provided with an opening station comprising peeling means for peeling the members apart to access each medicament dose. Suitably, the device is adapted for use where the peelable members are elongate sheets which define a plurality of medicament containers spaced along the length thereof, the device being provided with indexing means for indexing each container in turn. More preferably, the device is adapted for use where one of the sheets is a base sheet having a plurality of pockets therein, and the other of the sheets is a lid sheet, each pocket and the adjacent part of the lid sheet defining a respective one of the containers, the device comprising driving means for pulling the lid sheet and base sheet apart at the opening station. By metered dose inhaler (MDI) it is meant a medicament dispenser suitable for dispensing medicament in aerosol form, wherein the medicament is comprised
in an aerosol container suitable for containing a propellant-based aerosol medicament formulation. The aerosol container is typically provided with a metering valve, for example a slide valve, for release of the aerosol form medicament formulation to the patient. The aerosol container is generally designed to deliver a predetermined dose of medicament upon each actuation by means of the valve, which can be opened either by depressing the valve while the container is held stationary or by depressing the container while the valve is held stationary. Where the medicament container is an aerosol container, the valve typically comprises a valve body having an inlet port through which a medicament aerosol formulation may enter said valve body, an outlet port through which the aerosol may exit the valve body and an open/close mechanism by means of which flow through said outlet port is controllable. The valve may be a slide valve wherein the open/close mechanism comprises a sealing ring and receivable by the sealing ring a valve stem having a dispensing passage, the valve stem being slidably movable within the ring from a valve-closed to a valve-open position in which the interior of the valve body is in communication with the exterior of the valve body via the dispensing passage. Typically, the valve is a metering valve. The metering volumes are typically from 10 to 100 μl, such as 25 μl, 50 μl or 63 μl. Suitably, the valve body defines a metering chamber for metering an amount of medicament formulation and an open/close mechanism by means of which the flow through the inlet port to the metering chamber is controllable. Preferably, the valve body has a sampling chamber in communication with the metering chamber via a second inlet port, said inlet port being controllable by means of an open/close mechanism thereby regulating the flow of medicament formulation into the metering chamber. The valve may also comprise a 'free flow aerosol valve' having a chamber and a valve stem extending into the chamber and movable relative to the chamber between dispensing and non-dispensing positions. The valve stem has a configuration and the chamber has an internal configuration such that a metered volume is defined therebetween and such that during movement between is non- dispensing and dispensing positions the valve stem sequentially: (i) allows free flow of aerosol formulation into the chamber, (ii) defines a closed metered volume for pressurized aerosol formulation between the external surface of the valve stem and internal surface of the chamber, and (iii) moves with the closed metered volume within the chamber without decreasing the volume of the closed metered volume
until the metered volume communicates with an outlet passage thereby allowing dispensing of the metered volume of pressurized aerosol formulation. A valve of this type is described in U.S. Patent No. 5,772,085. Additionally, intra-nasal delivery of the present compounds is effective.
To formulate an effective pharmaceutical nasal composition, the medicament must be delivered readily to all portions of the nasal cavities (the target tissues) where it performs its pharmacological function. Additionally, the medicament should remain in contact with the target tissues for relatively long periods of time. The longer the medicament remains in contact with the target tissues, the medicament must be capable of resisting those forces in the nasal passages that function to remove particles from the nose. Such forces, referred to as 'mucociliary clearance', are recognised as being extremely effective in removing particles from the nose in a rapid manner, for example, within 10-30 minutes from the time the particles enter the nose. Other desired characteristics of a nasal composition are that it must not contain ingredients which cause the user discomfort, that it has satisfactory stability and shelf-life properties, and that it does not include constituents that are considered to be detrimental to the environment, for example ozone depletors. A suitable dosing regime for the formulation of the present invention when administered to the nose would be for the patient to inhale deeply subsequent to the nasal cavity being cleared. During inhalation the formulation would be applied to one nostril while the other is manually compressed. This procedure would then be repeated for the other nostril. A preferable means for applying the formulation of the present invention to the nasal passages is by use of a pre-compression pump. Most preferably, the pre- compression pump will be a VP7 model manufactured by Valois SA. Such a pump is beneficial as it will ensure that the formulation is not released until a sufficient force has been applied, otherwise smaller doses may be applied. Another advantage of the pre-compression pump is that atomisation of the spray is ensured as it will not release the formulation until the threshold pressure for effectively atomising the spray has been achieved. Typically, the VP7 model may be used with a bottle capable of holding 10-50ml of a formulation. Each spray will typically deliver 50-1 OOμl of such a formulation, therefore, the VP7 model is capable of providing at least 100 metered doses.
Examples of Nasal Formulations Example 1 : Nasal formulation containing active A formulation for intranasal delivery was prepared with ingredients as follows: to 100% Active 0.1% w/w
Polysorbate 80 0.025% w/w
Avicel RC591 1.5% w/w
Dextrose 5.0% w/w
BKC 0.015% w/w
EDTA 0.015% w/w water to 100% in a total amount suitable for 120 actuations and the formulation was filled into a bottle fitted with a metering valve adapted to dispense 50 or 100 μl per actuation. The device was fitted into a nasal actuator (Valois).
Example 2 : Nasal formulation containing active
A formulation for intranasal delivery was prepared with ingredients as follows: Active 0.005% w/w
Tyloxapol 2% w/w dextrose 5% w/w
BKC 0.015% w/w
EDTA 0.015% w/w water to 100% in a total amount suitable for 120 actuations and the formulation was filled into a bottle (plastic or glass) fitted with a metering valve adapted to dispense 50 or 100 μl per actuation The device was fitted into a nasal actuator (Valois, e.g. VP3, VP7 or VP7D)
Example 3 : Nasal formulation containing active
A formulation for intranasal delivery was prepared with ingredients as follows: active 0.05% w/w Triton X- 100 5% w/w
Dextrose 4% w/w
BKC 0.015% w/w
EDTA 0.015% w/w
water to 100% in a total amount suitable for 120 actuations and the formulation was filled into a bottle fitted with a metering valve adapted to dispense 50 or 100 μl per actuation.
Example 4 : Nasal formulation containing active
A formulation for intranasal delivery was prepared with ingredients as follows: active 0.05% w/w
Tyloxapol 5% w/w dextrose 5% w/w
BKC 0.015% w/w
EDTA 0.015% w/w water to 100% in a total amount suitable for 120 actuations and the formulation was filled into a bottle fitted with a metering valve adapted to dispense 50 or 100 μl per actuation The device was fitted into a nasal actuator (Valois). Throughout the specification and the claims which follow, unless the context requires otherwise, the word 'comprise', and variations such as 'comprises' and 'comprising', will be understood to imply the inclusion of a stated integer or step or group of integers but not to the exclusion of any other integer or step or group of integers or steps. All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth. The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows. The patents and patent applications described in this application are herein incorporated by reference.
Claims
1. A compound according to Formula I herein below:
C-| _4alkoxyC-| _4alkyl, C3_6cycloalkylC-| _4alkoxy, C-| ^alkoxycarbonyl,
C-|_4alkylsulfonyl, C-j^alkylsulfonyloxy, C-|_4alkylsulfonylC-|_4alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC-i^alkyl, C-|.4alkylsulfonamido, C-i^alkylamido,
C-| _4alkylsulfonamidoC-| .4alkyl, C-| ^alkylamidoCi _4alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC-|.4alkyl or a arylcarboxamidoC-|_4alkyl group; a group R3OCO(CH2)p, R3CON(R4)(CH2)p, R3R4NCO(CH2)p and
R3R4NSO2(CH2)pj where each of R3 and R4 is, independently, selected from a group consisting of a hydrogen atom and a C-|_4alkyl group or R3R4 forms part of a C3_6azacyloalkane or C3_g(2-oxo)azacycloalkane ring and p represents zero or an integer from 1 to 4; or a group Ar3-Z, wherein Ar3 represents an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring and Z represents a bond, O, S, or CH2; R2 is selected from a group consisting of a hydrogen atom or a Ci^alkyl group; q is 1 or 2; A is selected from the group consisting of a group of the formula (a), (b) (c) and (d): — Ar — Ar— Y— Ar2 (CH2)r— V— (CH2)sAr (a) (b) (c) (d)
wherein
Ar is selected from a group consisting of an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; or an optionally substituted bicyclic ring system; Ar1 and Ar2 each independently represent an optionally substituted phenyl ring or an optionally substituted 5- or 6- membered aromatic heterocyclic ring; and Y is selected from a group consisting of a bond, -NHCO-, -CONH-, -CH2-, or
-(CH2)mY1(CH )n-, wherein Y1 represents O, S, SO2, or CO and m and n each represent zero or 1 such that the sum of m+n is zero or 1 ; providing that when A represents a group of formula (a), any substituent present in Ar ortho to the carboxamide moiety is necessarily a hydrogen or a methoxy group; r and s are, independently, selected from a group consisting of an integer from zero to 3 such that the sum of r and s is equal to an integer from 1 to 4; and V is selected from a group consisting of a bond, O or S; and salts thereof.
2. A compound according to claim 1 consisting of the group selected from: trans-3-(2-(1-(4-(4-Quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1H-
3-benzazepine; fraπs-(E)-3-(2-(1 -(4-(3-(3-Methylsulfonyl)phenylpropenoyl) amino) cyclohexyl) ethyl)-2,3,4,5-tetrahydro-1b-3-benzazepine; trans-(£)-3-(2-(1-(4-(3-(4-Fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-3-(2-(1-(4-(2-lndolyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trat7S-3-(2-(1-(4-(3-(3-Pyridyl)phenyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; frat7S-3-(2-(1-(4-Phenylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1H-3- benzazepine; traπs-3-(2-(1-(4-(3-lndolyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 -/-3- benzazepine; frans-3-(2-(1-(4-(4-Quinolinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; frans-(E)-3-(2-(1-(4-(3-(4-Fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-6- methoxy-2,3,4,5-tetrahydro-1 H-3-benzazepine; f/-aπs-6-Methoxy-3-(2-(1-(4-(4-quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-6-Methoxy-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl)carboxamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1 -(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-(3-(5-methyl)-1 ,2,4-oxadiazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(3-acetylamino)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(6-(3,4-dihydro-3-oxo)-2H-benzoxazinyl)carboxamido)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 b-benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(6-(1 ,2-dihydro-2-oxo)quinolinyl)propenoyl)amino)- cyclohexyl) ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-fluoro-4-acetylamino)phenylpropenoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(8-(1 ,2-dihydro-2-oxo)quinolinyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; t/-ans-3-(2-(1-(4-(3-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)benzoyl)amino)cyclohexyl)ethyl)-
7-methylsulphonyl-2,3,4,5-tetrahydro-1 -/-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(E)-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(E)-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 -/-3-benzazepine; trans-(£)-7-(5-(3-Methyl)isoxazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(4-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine; ttans-7-Cyano-3-(2-(1-(4-(2,5-difluoro)phenylacetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(2,4- difluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(2,5- difluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-phenylpropanoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; frans-(E)-7-Cyano-3-(2-(1-(4-(3-(4- methoxy)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 b-3- benzazepine; traπs-(£)-7-Cyano-3-(2-(1-(4-(3-(2-acetyl)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 --3-benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(4-acetyl)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 -/-3-benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-cyano)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(3-cyano)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-7-Cyano-3-(2-(1-(4-(3-(5-(3-methyl)isoxazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(Z)-7-Cyano-3-(2-(1-(4-(3-phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; ans-(E)-7-Cyano-3-(2-(1-(4-(3-(2-pyridyl)propenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(1-(4-fluoro)naphthyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(E)-7-Cyano-3-(2-(1-(4-(3-(6- benzodioxanyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(3-(5-fluoro)indolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(3-(1-methyl)benzimidazolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(7-benzofuranyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; fraπs-(£)-7-Cyano-3-(2-(1-(4-(3-(5-(3-methyl)indolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; traπs-(£)-7-Cyano-3-(2-(1-(4-(3-(6-(2,3-dihydro-2-oxo)indolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 /--3-benzazepine; trans-7-Cyano-3-(2-(1-(2-benzofuranylacetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; fraπs-(£)-7-Cyano-3-(2-(1-(4-(3-(4-(2-methyl)indolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(E)-7-Cyano-3-(2-(1-(4-(3-(5-benzimidazolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(E)-7-Cyano-3-(2-(1-(4-(3-phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(2,3-methylenedioxy)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frar7s-(£)-7-Cyano-3-(2-(1-(4-(3-(3-(1-(2-oxo)pyrrolidinyl))phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-7-Cyano-3-(2-(1-(4-(2-indolylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-
1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(2-benzothiophenylacetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-(3-bromo)thiophenyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-(2-pyridyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 b/-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-(5-pyrimidinyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-(4-cyanophenyl)benzoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 --3-benzazepine; frans-(E)-7-Cyano-3-(2-(1-(4-(3-(2-thiophenyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-furanyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trat7S-(£)-7-Cyano-3-(2-(1-(4-(3-(3-thiophenyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(3-furanyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; traπs-(£)-7-Cyano-3-(2-(1-(4-(3-(4-quinolinyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-(E)-7-Cyano-3-(2-(1-(4-(3-(5-pyrimidinyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(2,4-difluoro)phenylacetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(6-(2-amino)benzothiazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; fraπs-7-Cyano-3-(2-(1-(4-(6-(2-methyl)benzothiazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; fra is-(£)-7-Cyano-3-(2-(1-(4-(3-(4-methylaminocarbonyl)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(5-(2-amino)benzoxazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-(1-pyrazolyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; frans-7-Cyano-3-(2-(1-(4-(2-thiophenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-benzothiophenyl)acetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-(2-(5-methyl)-1 ,3,4-oxadiazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; tra/7S-(£)-7-Cyano-3-(2-(1-(4-(3-(2-naphthyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frat7s-(£)-7-Cyano-3-(2-(1-(4-(3-(5-(3-acetyl)indolyl)propenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-7-Cyano-3-(2-(1-(4-(3-(5-(3-methyl)-1 ,2,4-oxadiazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(5-(2-methyl)benzimidazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(3-(2- acetyl)furanyl)propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trans-7-Cyano-3-(2-(1-(4-(6-(2-amino)benzoxazolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(2-benzothiophenyl)acetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-(£)-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-thienyl) propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(5-quinolinyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1 -(4-(3-(3-(5-Methyl)-1 ,2,4- oxadiazolyl) benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trat7s-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1 -(4-(8-(1 ,4-dihydro-4-oxo)quinolinyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trat7s-(E)-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; trar7s-(E)-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-acetamido-2- fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-acetyl)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 b-3-benzazepine; trat7s-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(2,4-difluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 /-/-3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(2-naphthyl)acetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frat7S-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(7-(3,4-dihydro-3-oxo)-2H- benzoxazinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frat7S-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(2-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; trans-3-(2-(1-(4-(5-(2-Methyl)quinolinyl)carboxamide)cyclohexyl)ethyl)-7- methanesulphonyloxy-2,3,4,5-tetrahydro-1 --3-benzazepine; trans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1 -(4-(2- indolyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(2-benzothiophenyl)acetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; frans-(£)-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-thienyl) propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(5-quinolinyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1 -(4-(8-(1 ,4-dihydro-4-oxo)quinolinyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1 -(4-(3-(3-(5-Methyl)-1 ,2,4- oxadiazolyl) benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(3-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-(3-(5-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(3-(2-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3-benzazepine; trans-7-(5-(3-Methyl)isoxazolyl)-3-(2-(1-(4-(2-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-7-(3-(5-Methyl)isoxazolyl)-3-(2-(1-(4-(4-fluoro)phenylacetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; tra/7S-(E)-7-(2-(5-Methyl)oxazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; fraπs-(E)-7-(3-(5-Methyl)isoxazolyl)-3-(2-(1-(4-(3-(4-fluoro)phenyl propenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-(E)-7-(5-Pyrimidyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 /--3-benzazepine; trans-7-(5-Pyrimidinyl)-3-(2-(1 -(4-(3-(3-(5-Methyl)-1 ,2,4- oxadiazolyl)benzoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-7-(3-(5-Methyl)isoxazolyl)-3-(2-(1-(4-(5-(2-methyl)quinolinyl)carboxamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; and trans-3-(2-(1-(4-(3-(2-(5-Methyl)oxazolyl)benzoyl)amino)cyclohexyl)ethyl)-7- methylsulphonyloxy-2,3,4,5-tetrahydro-1 --3-benzazepine.
3. A compound according to claim 1 consisting of the group selected from: traπs-7-Cyano-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl)carboxamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 /--3-benzazepine; trans-7-Cyano-3-(2-(1-(2-naphthylacetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-
1 7-3-benzazepine; trans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-(£)-7-Cyano-3-(2-(1-(4-(3-(3-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; traπs-7-Cyano-3-(2-(1 -(4-(8-(1 ,4-dihydro-4- oxo)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 -/-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(2-naphthyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; traπs-7-Cyano-3-(2-(1-(4-(2-naphthyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(2- methoxy)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; trans-(E)-7-Cyano-3-(2-(1-(4-(3-(3- methoxy)phenylpropenoyl)amino)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3- benzazepine; traπs-7-Cyano-3-(2-(1 -(4-(7-(1 ,2-dihydro-2- oxo)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 b-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(3-(3-(5-ethyl)-1 ,2,4-oxadiazolyl)benzoyl)amino)- cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1-(4-(1-naphthyl)acetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; frans-7-Cyano-3-(2-(1-(4-(6-(2,3-dihydro-2-oxo)indolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 --3-benzazepine; fraπs-7-Cyano-3-(2-(1-(4-(5-(2,3-dihydro-2-oxo)indolyl)acetamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1 -(4-(6-(1 ,2-dihydro-2- oxo)quinolinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-7-Cyano-3-(2-(1 -(4-(7-(1 ,2-dihydro-2- oxo)quinolinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-7-Cyano-3-(2-(1-(4-(6-quinoxalinyl)acetamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-3-benzazepine; frans-7-Cyano-3-(2-(1-(4-(6-(3,4-dihydro-2-oxo)-2H-benzoxazinyl)acetamido) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-Cyano-3-(2-(1-(4-(3-(2-fluoro-5-acetamido)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-7-(5-(3-Methyl)-1 ,2,4-oxadiazolyl)-3-(2-(1-(4-(5-(2-methyl)quinolinyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-3-(2-(1-(4-(3-(2-(4-Methyl)oxazolyl)benzoyl)amino)cyclohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-3-(2-(1-(4-(3-trifluoromethylbenzoyl)amino)cyclohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1 --3-benzazepine; frans-7-(5-Pyrimidinyl)-3-(2-(1-(4-(5-(2- methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 --3- benzazepine; trans-(£)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(2-cyano)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(3-cyano)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 7-3-benzazepine; and frans-(£)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(4-cyano)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine.
4. A compound according to claim 1 selected from the group consisting of: trans-(£)-7-Cyano-3-(2-(1-(4-(5-quinolinyl)carboxamido)cyclohexyl)ethyl)-2,3,4,5- tetrahydro-1 H-benzazepine; trans-7-Cyano-3-(2-(1-(4-(5-(8-fluoro)quinolinyl)carboxamido)cyclohexyl)ethyl)-
2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-3-(2-(1-(4-(5-(2-Methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1 --3-benzazepine; trans-3-(2-(1-(4-(5-(2-Methyl)quinolinyl)carboxamide)cyclohexyl)ethyl)-7- methanesulphonyloxy-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino)cyclohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-3-(2-(1-(4-(5-(8-Chloro-2-methyl)quinolinyl)carboxamide)cyclohexyl)ethyl)-7- methanesulphonyl-2,3,4,5-tetrahydro-1 H-3-benzazepine; trar?s-(E)-7-(2-Pyridyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-(£)-7-(2-Pyrimidyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; trans-(£)-7-(1-Pyrrolidinylcarbonyl)-3-(2-(1-(4-(3-(4-fluoro)phenylpropenoyl)amino) cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-7-(1-Pyrrolidinylcarbonyl)-3-(2-(1-(4-(3-pyrrolo[2,3-b]pyridyl) carboxamido)cyclohexyl)ethyl)-2,3,4,5-tetrahydro-1 H-3-benzazepine; frans-3-(2-(1-(4-(5-(8-Fluoro-2-methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-7- methylsulphonyl-2,3,4,5-tetrahydro-1 --3-benzazepine; trans-3-(2-(1-(4-(5-(8-Fluoro-2-methyl)quinolinyl)carboxamido)cyclohexyl)ethyl)-7- methylsulphonyloxy-2,3,4,5-tetrahydro-1 H-3-benzazepine.
5. A pharmaceutical composition for the treatment of muscarinic acetylcholine receptor mediated diseases comprising a compound according to claim 1 and a pharmaceutically acceptable carrier thereof.
6. A method of inhibiting the binding of acetylcholine to its receptors in a mammal in need thereof comprising administering a safe and effective amount of a compound according to claim 1.
7. A method of treating a muscarinic acetylcholine receptor mediated disease, wherein acetylcholine binds to said receptor, comprising administering a safe and effective amount of a compound according to claim 1.
8. A method according to claim 7 wherein the disease is selected from the group consisting of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema and allergic rhinitis.
9. A method according to claim 8 wherein administration is via inhalation via the mouth or nose.
10. A method according to claim 9 wherein administration is via a medicament dispenser selected from a reservoir dry powder inhaler, a multi-dose dry powder inhaler or a metered dose inhaler.
11. A method according to claim 10 wherein the compound is administered to a human and has a duration of action of 12 hours or more for a 1 mg dose.
12. A method according to claim 11 wherein the compound has a duration of action of 24 hours or more.
13. A method according to claim 12 wherein the compound has a duration of action of 36 hours or more.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04821848A EP1725241A4 (en) | 2004-03-17 | 2004-03-17 | M3 muscarinic acetylcholine receptor antagonists |
| PCT/US2004/008032 WO2005094835A1 (en) | 2004-03-17 | 2004-03-17 | M3 muscarinic acetylcholine receptor antagonists |
| US10/598,888 US20070185088A1 (en) | 2004-03-17 | 2004-03-17 | M3 muscarinic acetylchoine receptor antagonists |
| JP2007503878A JP2007529514A (en) | 2004-03-17 | 2004-03-17 | M3 muscarinic acetylcholine receptor antagonist |
| TW094107753A TW200600500A (en) | 2004-03-17 | 2005-03-15 | M3 muscarinic acetylcholine receptor antagonists |
| ARP050100995A AR048317A1 (en) | 2004-03-17 | 2005-03-15 | DERIVATIVES OF BENZOAZEPINE AS ANTAGONISTS OF THE ACETILCOLINE MUSCARINIC RECEPTOR AND PHARMACEUTICAL COMPOSITIONS. |
| PE2005000294A PE20060122A1 (en) | 2004-03-17 | 2005-03-15 | BENZAZEPINE COMPOUNDS AS ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M3 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2004/008032 WO2005094835A1 (en) | 2004-03-17 | 2004-03-17 | M3 muscarinic acetylcholine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005094835A1 true WO2005094835A1 (en) | 2005-10-13 |
Family
ID=35063506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2004/008032 WO2005094835A1 (en) | 2004-03-17 | 2004-03-17 | M3 muscarinic acetylcholine receptor antagonists |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070185088A1 (en) |
| EP (1) | EP1725241A4 (en) |
| JP (1) | JP2007529514A (en) |
| AR (1) | AR048317A1 (en) |
| PE (1) | PE20060122A1 (en) |
| TW (1) | TW200600500A (en) |
| WO (1) | WO2005094835A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
| US8067408B2 (en) | 2008-02-06 | 2011-11-29 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
| US8071588B2 (en) | 2008-02-06 | 2011-12-06 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
| US8084449B2 (en) | 2008-02-06 | 2011-12-27 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200519108A (en) * | 2003-07-17 | 2005-06-16 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| MXPA06004242A (en) * | 2003-10-17 | 2006-06-28 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists field of the invention. |
| PE20050489A1 (en) * | 2003-11-04 | 2005-09-02 | Glaxo Group Ltd | ANTAGONISTS OF MUSCARINE ACETYLCHOLINE RECEPTORS |
| WO2005087236A1 (en) * | 2004-03-11 | 2005-09-22 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
| EP1725238A4 (en) * | 2004-03-17 | 2009-04-01 | Glaxo Group Ltd | M 3 muscarinic acetylcholine receptor antagonists |
| JP2007529513A (en) * | 2004-03-17 | 2007-10-25 | グラクソ グループ リミテッド | M3 muscarinic acetylcholine receptor antagonist |
| MY144753A (en) | 2004-04-27 | 2011-10-31 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
| WO2005112644A2 (en) * | 2004-05-13 | 2005-12-01 | Glaxo Group Limited | Muscarinic acetylcholine receptor antagonists |
| WO2006055553A2 (en) * | 2004-11-15 | 2006-05-26 | Glaxo Group Limited | Novel m3 muscarinic acetylcholine receptor antagonists |
| EP1937267A4 (en) * | 2005-08-02 | 2009-08-26 | Glaxo Group Ltd | M3 muscarinic acetylcholine receptor antagonists |
| JP2009504768A (en) * | 2005-08-18 | 2009-02-05 | グラクソ グループ リミテッド | Muscarinic acetylcholine receptor antagonist |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605607B1 (en) * | 1998-10-08 | 2003-08-12 | Smithkline Beecham P.L.C. | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2342432A1 (en) * | 2001-03-28 | 2002-09-28 | Christopher Norbert Johnson | Novel compound |
-
2004
- 2004-03-17 JP JP2007503878A patent/JP2007529514A/en not_active Withdrawn
- 2004-03-17 US US10/598,888 patent/US20070185088A1/en not_active Abandoned
- 2004-03-17 EP EP04821848A patent/EP1725241A4/en not_active Withdrawn
- 2004-03-17 WO PCT/US2004/008032 patent/WO2005094835A1/en active Application Filing
-
2005
- 2005-03-15 AR ARP050100995A patent/AR048317A1/en unknown
- 2005-03-15 TW TW094107753A patent/TW200600500A/en unknown
- 2005-03-15 PE PE2005000294A patent/PE20060122A1/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6605607B1 (en) * | 1998-10-08 | 2003-08-12 | Smithkline Beecham P.L.C. | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents) |
Non-Patent Citations (3)
| Title |
|---|
| AUSTIN N.E. ET AL: "Novel 2,3,4,5-Tetrahydro-1H-3-benzyzepines with high Affinity and Selectivity for the Dopamine D.sub.3 Receptor.", BIOORGANIC& MEDICINAL CHEMISTRY LETTERS, vol. 10, no. 22, 20 November 2000 (2000-11-20), pages 2553 - 2555, XP004224262 * |
| MACDONALD G.J. ET AL: "Design and Synthesis of trans-3(2-(4-((3-(3-(5-Methyl-1,2,4-oxadiozolyl))-phenyl)carboxamido)cyclohexyl)ethyl)-7-methylsulfonyl-2,3,4,5-tetrahydro1H-3-benzazepine (SB-414796): A Potent and Selective Dopamine D.sub.3 Receptor Antagonist.", JOURNAL OF MEDICINAL CHEMISTRY., vol. 46, no. 23, 6 November 2003 (2003-11-06), pages 4952 - 4964, XP002994764 * |
| See also references of EP1725241A4 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8067408B2 (en) | 2008-02-06 | 2011-11-29 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
| US8071588B2 (en) | 2008-02-06 | 2011-12-06 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
| US8084449B2 (en) | 2008-02-06 | 2011-12-27 | Glaxo Group Limited | Dual pharmacophores—PDE4-muscarinic antagonistics |
| WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1725241A4 (en) | 2009-03-25 |
| US20070185088A1 (en) | 2007-08-09 |
| PE20060122A1 (en) | 2006-02-26 |
| AR048317A1 (en) | 2006-04-19 |
| JP2007529514A (en) | 2007-10-25 |
| TW200600500A (en) | 2006-01-01 |
| EP1725241A1 (en) | 2006-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1119563B1 (en) | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | |
| US8450317B2 (en) | CXCR3 receptor antagonists | |
| EP1725241A1 (en) | M3 muscarinic acetylcholine receptor antagonists | |
| KR101037026B1 (en) | Muscarinic acetylcholine receptor antagonists | |
| EP1725240A1 (en) | Muscarinic acetylcholine receptor antagonists | |
| CA2588768A1 (en) | Aromatic amide derivatives, medicinal compositions containing the same, medical uses of both | |
| US7232841B2 (en) | M3 muscarinic acetylcholine receptor antagonists | |
| CN101981003A (en) | Amide compounds, compositions and uses thereof | |
| WO2003093231A2 (en) | Tetrahydropyranyl cyclopentyl tetrahydroisoquinoline modulators of chemokine receptor activity | |
| WO2004085385A2 (en) | Cannabinoid receptor ligands | |
| WO2007018514A1 (en) | Novel m3 muscarinic acetylcholine receptor antagonists | |
| WO2005047250A1 (en) | N-acylated-3- (benzoyl) - pyrrolidines as 11-beta-hsd1 inhibitors useful for the treatment of metabolic disorders. | |
| EP1725238A2 (en) | M 3 muscarinic acetylcholine receptor antagonists | |
| EP1725564A1 (en) | M3 muscarinic acetylcholine receptor antagonists | |
| AU2010205630A1 (en) | 6-phenyl-LH-imidazo [4, 5-c] pyridine-4-carbonitrile derivatives as cathepsin S and/or cathepsin K inhibitors | |
| WO2008100635A1 (en) | 1- [3- (monocyclic amino) propyl] - 4, 5, 6, 7-tetrahydro-1h-pyrazolo [4, 3-c] -pyridines as modulators of cathepsin s | |
| MXPA01003645A (en) | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) | |
| AU2003266336A1 (en) | Dibenzoxazepine | |
| KR20030061459A (en) | Carbazole derivatives and their use as neuropeptide y5 receptor ligands | |
| ZA200102758B (en) | Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 Receptors (antipsychotic agents). |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 10598888 Country of ref document: US Ref document number: 2007185088 Country of ref document: US |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2007503878 Country of ref document: JP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004821848 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004821848 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 10598888 Country of ref document: US |